<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">JIC</journal-id>
         <journal-id journal-id-type="hwp">spjic</journal-id>
         <journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
         <journal-title>Journal of Intensive Care Medicine</journal-title>
         <issn pub-type="ppub">0885-0666</issn>
         <issn pub-type="epub">1525-1489</issn>
         <publisher>
            <publisher-name>SAGE Publications</publisher-name>
            <publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.1177/0885066611408692</article-id>
         <article-id pub-id-type="publisher-id">10.1177_0885066611408692</article-id>
         <article-categories>
            <subj-group subj-group-type="heading">
               <subject>Analytic Reviews</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Hepatorenal Syndrome in the Intensive Care Unit</article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" corresp="yes" xlink:type="simple">
               <name name-style="western">
                  <surname>Wadei</surname>
                  <given-names>Hani M.</given-names>
               </name>
               <degrees>MD</degrees>
               <xref ref-type="aff" rid="aff1-0885066611408692">1</xref>
               <xref ref-type="corresp" rid="corresp1-0885066611408692"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Gonwa</surname>
                  <given-names>Thomas A.</given-names>
               </name>
               <degrees>MD</degrees>
               <xref ref-type="aff" rid="aff1-0885066611408692">1</xref>
            </contrib>
         </contrib-group>
         <aff id="aff1-0885066611408692">
            <label>1</label>Department of Transplantation, College of Medicine, Mayo Clinic, Jacksonville, FL, USA</aff>
         <author-notes>
            <corresp id="corresp1-0885066611408692">Hani M. Wadei, Department of Transplantation, Mayo Clinic, 4500 San Pablo Road., Jacksonville, FL 32224, USA. Email: <email xlink:type="simple">wadei.hani@mayo.edu</email>
            </corresp>
         </author-notes>
         <pub-date pub-type="epub-ppub">
            <month>3</month>
            <year>2013</year>
         </pub-date>
         <volume>28</volume>
         <issue>2</issue>
         <fpage>79</fpage>
         <lpage>92</lpage>
         <history>
            <date date-type="received">
               <day>28</day>
               <month>9</month>
               <year>2010</year>
            </date>
            <date date-type="rev-recd">
               <day>22</day>
               <month>12</month>
               <year>2010</year>
            </date>
            <date date-type="accepted">
               <day>14</day>
               <month>2</month>
               <year>2011</year>
            </date>
         </history>
         <permissions>
            <copyright-statement>© The Author(s) 2011</copyright-statement>
            <copyright-year>2011</copyright-year>
            <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
         </permissions>
         <abstract>
            <p>Hepatorenal syndrome (HRS) is a functional form of acute kidney injury (AKI) associated with advanced liver cirrhosis or fulminant hepatic failure. Various new concepts have emerged since the initial diagnostic criteria and definition of HRS was initially published. These include better understanding of the pathophysiological mechanisms involved in HRS, identification of bacterial infection (especially spontaneous bacterial peritonitis) as the most important HRS-precipitating event, recognition that insufficient cardiac output plays a role in the occurrence of HRS, and evidence that renal failure reverses with pharmacotherapy. Patients with HRS are often critically ill and, by definition, have multiorgan failure. The purpose of this review is to provide an update on novel advances in HRS, with emphasis on the different aspects of management of these patients in the intensive care unit.</p>
         </abstract>
         <kwd-group>
            <kwd>acute kidney injury</kwd>
            <kwd>liver cirrhosis</kwd>
            <kwd>vasopressin analogs</kwd>
            <kwd>liver transplantation</kwd>
            <kwd>simultaneous liver-kidney transplantation</kwd>
         </kwd-group>
         <custom-meta-wrap>
            <custom-meta xlink:type="simple">
               <meta-name>cover-date</meta-name>
               <meta-value>March/April 2013</meta-value>
            </custom-meta>
         </custom-meta-wrap>
      </article-meta>
   </front>
   <body>
      <sec id="section1-0885066611408692">
         <title>Introduction</title>
         <p>Acute kidney injury (AKI) often develops in patients with hepatic cirrhosis, and in many cases it necessitates admission to the intensive care unit. Potential causes of AKI in patients with cirrhosis are diverse and sometimes hard to differentiate. Hepatorenal syndrome (HRS) is a form of functional renal failure that is specific only to patients with end-stage liver disease or fulminant hepatic failure and is related to intense renal vasoconstriction. Renal histology shows no pathological changes severe enough to justify the deterioration in renal function, and kidney function recovers following liver transplantation or when kidneys from patients with HRS are transplanted in healthy participants.<sup>
               <xref ref-type="bibr" rid="bibr1-0885066611408692">1</xref>,<xref ref-type="bibr" rid="bibr2-0885066611408692">2</xref>
            </sup> Because of its poor prognosis and lack of effective therapy, the term “terminal functional renal failure” was synonymous with HRS.<sup>
               <xref ref-type="bibr" rid="bibr3-0885066611408692">3</xref>
            </sup> Over the last 2 decades, major advances in our understanding of the pathophysiological mechanisms involved in HRS and the availability of pharmacological and nonpharmacological interventions have translated into improvement in the short-term survival of patients with HRS, but without liver transplantation, long-term survival remains dismal. The challenging role of the intensivist is to prolong the survival of patients with HRS long enough to receive transplant.</p>
      </sec>
      <sec id="section2-0885066611408692">
         <title>Pathophysiology</title>
         <p>The key pathophysiological change responsible for HRS development in patients with cirrhosis is arterial vasodilatation, which occurs primarily in the splanchnic circulation and is mediated by the release of potent vasodilators, the most important of which is nitric oxide (NO).<sup>
               <xref ref-type="bibr" rid="bibr4-0885066611408692">4</xref>
            </sup> Nitric oxide production is increased in cirrhosis due to shear stress-induced upregulation of endothelial NO synthase (eNOS) activity in the splanchnic and systemic circulations, as well as endotoxin-mediated eNOS activation.<sup>
               <xref ref-type="bibr" rid="bibr5-0885066611408692">5</xref>,<xref ref-type="bibr" rid="bibr6-0885066611408692">6</xref>
            </sup> Increased inducible NOS (iNOS) activity has also been documented.<sup>
               <xref ref-type="bibr" rid="bibr7-0885066611408692">7</xref>
            </sup> With arterial vasodilatation, the resultant decrease in effective blood volume activates the renin-angiotensin-aldosterone system (RAAS), unloads the high-pressure baroreceptors in the carotid body and aortic arch with subsequent activation of the sympathetic nervous system (SNS), and induces nonosmotic release of vasopressin. These changes lead to intense renal vasoconstriction and reduced glomerular filtration rate (GFR). Other vascular beds show similar changes, and studies have correlated renal blood flow with blood flow in the cerebral, femoral, and upper extremities in patients with HRS.<sup>
               <xref ref-type="bibr" rid="bibr8-0885066611408692">8</xref>
               <xref ref-type="bibr" rid="bibr9-0885066611408692"/>–<xref ref-type="bibr" rid="bibr10-0885066611408692">10</xref>
            </sup> With worsening of the liver disease and progression of cirrhosis, further splanchnic vasodilation occurs, creating a vicious cycle that favors further activation of the RAAS, SNS, and vasopressin release, and subsequent intensification of renal vasoconstriction.<sup>
               <xref ref-type="bibr" rid="bibr4-0885066611408692">4</xref>
            </sup> Hepatorenal syndrome constitutes the end of the spectrum of these pathophysiological derangements, which start long before HRS manifests clinically. <xref ref-type="table" rid="table1-0885066611408692">Table 1</xref>
and <xref ref-type="fig" rid="fig1-0885066611408692">Figure 1</xref>
summarize the different pathophysiological changes occurring in cirrhotic patients from early disease stage (preascites) to HRS. It is important to mention that other mechanisms may also be responsible for the early sodium retention in cirrhotic patients.<sup>
               <xref ref-type="bibr" rid="bibr11-0885066611408692">11</xref>
            </sup>
         </p>
         <table-wrap id="table1-0885066611408692" position="float">
            <label>Table 1.</label>
            <caption>
               <p>Hemodynamic Changes Occurring in Different Stages of Cirrhosis.</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table1-0885066611408692" position="float" xlink:href="10.1177_0885066611408692-table1.tif" xlink:type="simple"/>
            <table>
               <thead>
                  <tr>
                     <th colspan="1" rowspan="1">
</th>
                     <th align="center" colspan="1" rowspan="1">Compensated Cirrhosis (Preascites)</th>
                     <th align="center" colspan="1" rowspan="1">Diuretic-Responsive Ascites</th>
                     <th align="center" colspan="1" rowspan="1">Diuretic-Resistant (refractory) Ascites</th>
                     <th align="center" colspan="1" rowspan="1">HRS</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Splanchnic and systemic arterial vasodilatation</td>
                     <td colspan="1" rowspan="1">Normal to +</td>
                     <td colspan="1" rowspan="1">+</td>
                     <td colspan="1" rowspan="1">++</td>
                     <td colspan="1" rowspan="1">+++</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Effective circulating volume</td>
                     <td colspan="1" rowspan="1">Normal</td>
                     <td colspan="1" rowspan="1">-</td>
                     <td colspan="1" rowspan="1">--</td>
                     <td colspan="1" rowspan="1">---</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Renin, aldosterone, vasopressin, and norepinephrine</td>
                     <td colspan="1" rowspan="1">Normal</td>
                     <td colspan="1" rowspan="1">+</td>
                     <td colspan="1" rowspan="1">++</td>
                     <td colspan="1" rowspan="1">+++</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Renal sodium retention</td>
                     <td colspan="1" rowspan="1">+</td>
                     <td colspan="1" rowspan="1">++</td>
                     <td colspan="1" rowspan="1">+++</td>
                     <td colspan="1" rowspan="1">++++</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Plasma volume</td>
                     <td colspan="1" rowspan="1">+</td>
                     <td colspan="1" rowspan="1">++</td>
                     <td colspan="1" rowspan="1">+++</td>
                     <td colspan="1" rowspan="1">++++</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Renal vasoconstriction</td>
                     <td colspan="1" rowspan="1">Normal</td>
                     <td colspan="1" rowspan="1">Normal</td>
                     <td colspan="1" rowspan="1">++</td>
                     <td colspan="1" rowspan="1">++++</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn id="table-fn1-0885066611408692">
                  <p>Abbreviations: HRS, hepatorenal syndrome; +, mild increase; ++, moderate increase; +++, severe increase; ++++, very severe increase; -, mild decrease; --, moderate decrease; ---, severe decrease.</p>
               </fn>
            </table-wrap-foot>
         </table-wrap>
         <fig id="fig1-0885066611408692" position="float">
            <label>Figure 1.</label>
            <caption>
               <p>Pathophysiological mechanisms involved in HRS. HRS indicates hepatorenal syndrome. Adapted with permission from Wadei et al.<sup>
                     <xref ref-type="bibr" rid="bibr130-0885066611408692">130</xref>
                  </sup>
               </p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_0885066611408692-fig1.tif" xlink:type="simple"/>
         </fig>
         <p>In the kidney, the renal vasoconstriction is counterbalanced by increased intrarenal production of vasodilating prostaglandins and kallikreins. Indeed, urinary excretion of vasodilating prostaglandins is higher in patients with ascitic cirrhosis compared to normal participants with subsequent decline in urinary prostaglandin excretion in those with HRS.<sup>
               <xref ref-type="bibr" rid="bibr12-0885066611408692">12</xref>,<xref ref-type="bibr" rid="bibr13-0885066611408692">13</xref>
            </sup> Similarly, the administration of cyclooxygenase inhibitors to patients with ascitic cirrhosis precipitate HRS, indicating a role of vasodilating prostaglandins in maintaining GFR.<sup>
               <xref ref-type="bibr" rid="bibr14-0885066611408692">14</xref>
            </sup> Immnohistochemical studies have documented reduced cyclooxygenase staining in renal medullary tissue of patients with HRS, while the enzyme shows normal expression in kidneys of patients with other cause of AKI.<sup>
               <xref ref-type="bibr" rid="bibr15-0885066611408692">15</xref>
            </sup> Factors associated with reduced prostaglandin production in HRS are unknown but intense renal vasoconstriction may contribute to reduced prostaglandin synthesis.<sup>
               <xref ref-type="bibr" rid="bibr16-0885066611408692">16</xref>
            </sup>
         </p>
         <p>In addition to the vascular changes outlined above, recent studies indicate that a relative inadequacy in cardiac output (CO) contributes to the renal hypoperfusion. The role of cardiac dysfunction in HRS was studied by Ruiz-del-Arbol et al<sup>
               <xref ref-type="bibr" rid="bibr17-0885066611408692">17</xref>
            </sup> who demonstrated reduction in CO at time of diagnosis of spontaneous bacterial peritonitis (SBP) without a change in systemic vascular resistance in patients who had cirrhosis and subsequently developed HRS. Cardiac output further decreased after resolution of infection in the HRS group but not in those without renal failure.<sup>
               <xref ref-type="bibr" rid="bibr17-0885066611408692">17</xref>
            </sup> The same group studied the systemic and hepatic hemodynamics of 66 patients with cirrhosis and tense ascites and normal serum creatinine at baseline with repeat measurement in 27 patients who subsequently developed HRS. At baseline, arterial BP and CO were significantly lower, whereas RAAS and SNS activity were significantly higher in the group that developed HRS with further reduction in CO at the onset of renal dysfunction.<sup>
               <xref ref-type="bibr" rid="bibr18-0885066611408692">18</xref>
            </sup> The mechanism of impaired cardiac function is complex and may include (1) neurohumoral hyperactivity leading to myocardium growth and fibrosis with disturbed relaxation, (2) diminished myocardial β-adrenergic receptor signal transduction, and (3) an inhibitory effect of circulating cytokines, including tumor necrosis factor-α (TNF-α) and NO, on ventricular function.<sup>
               <xref ref-type="bibr" rid="bibr19-0885066611408692">19</xref>
               <xref ref-type="bibr" rid="bibr20-0885066611408692"/>–<xref ref-type="bibr" rid="bibr21-0885066611408692">21</xref>
            </sup> In alcoholic patients, a variable degree of alcoholic cardiomyopathy can also be a contributing factor.</p>
         <p>Two recent studies indicate that relative adrenal dysfunction is common in patients with cirrhosis and might play a role in the pathophysiology of HRS especially in the intensive care setting.<sup>
               <xref ref-type="bibr" rid="bibr22-0885066611408692">22</xref>,<xref ref-type="bibr" rid="bibr23-0885066611408692">23</xref>
            </sup> In the first study, adrenal insufficiency was detected in 80% of patients with HRS but only in 34% with serum creatinine below 1.5 mg/dL.<sup>
               <xref ref-type="bibr" rid="bibr22-0885066611408692">22</xref>
            </sup> Since normal adrenal function is essential for an adequate response of the arterial circulation to endogenous vasoconstrictors, adrenal insufficiency could be an important contributory mechanism of circulatory dysfunction associated with HRS, especially in patients with severe bacterial infections. Other features associated with adrenal insufficiency were severe liver failure, arterial hypotension, vasopressor dependency, and increased hospital mortality.<sup>
               <xref ref-type="bibr" rid="bibr22-0885066611408692">22</xref>
            </sup> The second study showed that treatment with hydrocortisone in patients with cirrhosis with severe sepsis and adrenal insufficiency is associated with a rapid improvement in systemic hemodynamics, reduction of vasopressor requirements, and lower hospital mortality.<sup>
               <xref ref-type="bibr" rid="bibr23-0885066611408692">23</xref>
            </sup> The mechanisms of adrenal dysfunction in cirrhosis with severe sepsis have not been explored, but a reduction in adrenal blood flow secondary to regional vasoconstriction is a possible mechanism.</p>
      </sec>
      <sec id="section3-0885066611408692">
         <title>Diagnosis of HRS and its Evolution</title>
         <p>Pinpointing the etiology of AKI in patients with cirrhosis is important for both prognostic and therapeutic purposes (discussed below). In HRS, the tubular function is preserved with the absence of proteinuria or histological changes in the kidney. Urine sodium level is usually very low (&lt;10 mEq/L), which differentiates HRS from acute tubular necrosis (ATN). There is no diagnostic test for HRS, and the diagnosis relies mainly on excluding other causes of renal failure in cirrhosis and relying on established diagnostic criteria.<sup>
               <xref ref-type="bibr" rid="bibr24-0885066611408692">24</xref>
            </sup> Type 1 HRS is defined as doubling of the serum creatinine to a level &gt;2.5 mg/dL in &lt;2 weeks' duration, whereas in type 2 HRS there is a gradual rise in serum creatinine to &gt;1.5 mg/dL. The diagnostic criteria of HRS were originally developed in a consensus meeting of the International Ascites Club (IAC) in 1996<sup>
               <xref ref-type="bibr" rid="bibr25-0885066611408692">25</xref>
            </sup> and were subsequently modified in 2007 (<xref ref-type="table" rid="table2-0885066611408692">Table 2</xref>
).<sup>
               <xref ref-type="bibr" rid="bibr26-0885066611408692">26</xref>
            </sup> The main points of difference between the 2 definitions are as follows:<list list-type="order">
               <list-item>
                  <p>Creatinine clearance is no longer incorporated in the diagnosis.</p>
               </list-item>
               <list-item>
                  <p>2.Ongoing bacterial infection does not exclude the diagnosis of HRS, provided septic shock is not present.</p>
               </list-item>
               <list-item>
                  <p>Albumin is preferred to saline for plasma volume expansion.</p>
               </list-item>
               <list-item>
                  <p>Nonessential minor diagnostic criteria including low urine sodium level have been omitted.</p>
               </list-item>
            </list>
         </p>
         <table-wrap id="table2-0885066611408692" position="float">
            <label>Table 2.</label>
            <caption>
               <p>Diagnostic Criteria of HRS.</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table2-0885066611408692" position="float" xlink:href="10.1177_0885066611408692-table2.tif" xlink:type="simple"/>
            <table>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Cirrhosis with ascites</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Serum creatinine &gt;1.5 mg/dL</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">No improvement in serum creatinine (a decrease in serum &lt;1.5 mg/dL) after 2 days off diuretics and volume expansion with albumin (1 g/kg body weight up to a maximum of 100 g/d)</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Absence of shock</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">No current or recent treatment with nephrotoxic drugs</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Absence of signs of parenchymal renal disease, as suggested by protienuria (&gt;500 mg/d) or hematuria (&gt;50 red blood cells per high-power field) and/or abnormal renal ultrasound</td>
                  </tr>
               </tbody>
            </table>
            <table-wrap-foot>
               <fn id="table-fn2-0885066611408692">
                  <p>Adapted from Salerno et al.<sup>
                        <xref ref-type="bibr" rid="bibr26-0885066611408692">26</xref>
                     </sup>
                  </p>
               </fn>
            </table-wrap-foot>
         </table-wrap>
         <p>It is important to think of the 2 types of HRS, type 1 and type 2, as 2 different clinical entities rather than stages of progression of the same disease. Type 1 HRS is more acute, commonly follows a precipitating event, is associated with multiorgan failure, has a very grim prognosis, and overlaps with other causes of AKI. In many cases, it is virtually impossible to separate type 1 HRS from ATN. Type 2 HRS can be considered the genuine form of renal failure in cirrhotics. It represents the extreme expression of cirrhosis-induced circulatory failure and is heralded by refractory ascites. Renal failure in type 2 HRS is slowly progressive and parallels the degree of deterioration in liver function. The median survival for patients with type 2 HRS is 6 months, whereas the survival for patients with type 1 HRS is only 10% at 90 days from diagnosis.<sup>
               <xref ref-type="bibr" rid="bibr27-0885066611408692">27</xref>
            </sup> 
            <xref ref-type="table" rid="table3-0885066611408692">Table 3</xref>
highlights the major differences between type 1 and type 2 HRS. <xref ref-type="fig" rid="fig2-0885066611408692">Figure 2</xref>
shows the probability of survival in patients with type 1 and type 2 HRS, compared to cirrhotic patients with ascites and no HRS.</p>
         <table-wrap id="table3-0885066611408692" position="float">
            <label>Table 3.</label>
            <caption>
               <p>Characteristics of Type 1 and Type 2 Hepatorenal Syndrome (HRS).</p>
            </caption>
            <graphic alt-version="no" alternate-form-of="table3-0885066611408692" position="float" xlink:href="10.1177_0885066611408692-table3.tif" xlink:type="simple"/>
            <table>
               <thead>
                  <tr>
                     <th colspan="1" rowspan="1">
</th>
                     <th align="center" colspan="1" rowspan="1">Course</th>
                     <th align="center" colspan="1" rowspan="1">Precipitating Event</th>
                     <th align="center" colspan="1" rowspan="1">History of Diuretic-Resistant Ascites</th>
                     <th align="center" colspan="1" rowspan="1">Prognosis</th>
                  </tr>
               </thead>
               <tbody>
                  <tr>
                     <td colspan="1" rowspan="1">Type 1 HRS</td>
                     <td colspan="1" rowspan="1">Precipitous doubling of serum creatinine in &lt;2 weeks</td>
                     <td colspan="1" rowspan="1">Present in &gt;50% of cases</td>
                     <td colspan="1" rowspan="1">May or may not be present</td>
                     <td colspan="1" rowspan="1">Without therapy, 90-day survival of 10%</td>
                  </tr>
                  <tr>
                     <td colspan="1" rowspan="1">Type 2 HRS</td>
                     <td colspan="1" rowspan="1">Gradually progressive</td>
                     <td colspan="1" rowspan="1">Absent</td>
                     <td colspan="1" rowspan="1">Always present</td>
                     <td colspan="1" rowspan="1">Median survival, 6 months</td>
                  </tr>
               </tbody>
            </table>
         </table-wrap>
         <fig id="fig2-0885066611408692" position="float">
            <label>Figure 2.</label>
            <caption>
               <p>Probability of survival in patients with type 1 and type 2 HRS compared to cirrhotic patients with ascites and normal kidney function. HRS indicates hepatorenal syndrome. Adapted with permission from Arroyo et al.<sup>
                     <xref ref-type="bibr" rid="bibr131-0885066611408692">131</xref>
                  </sup>
               </p>
            </caption>
            <graphic alt-version="no" position="float" xlink:href="10.1177_0885066611408692-fig2.tif" xlink:type="simple"/>
         </fig>
      </sec>
      <sec id="section4-0885066611408692">
         <title>Precipitating and Contributing Factors</title>
         <p>In type 1 HRS, a precipitating event is identified in 70% to 100% of patients with HRS and more than 1 event can occur in a single patient.<sup>
               <xref ref-type="bibr" rid="bibr28-0885066611408692">28</xref>
               <xref ref-type="bibr" rid="bibr29-0885066611408692"/>
               <xref ref-type="bibr" rid="bibr30-0885066611408692"/>–<xref ref-type="bibr" rid="bibr31-0885066611408692">31</xref>
            </sup> Identifiable precipitating factors include bacterial infections, large volume paracentesis without albumin infusion, gastrointestinal bleeding, and acute alcoholic hepatitis. Of the bacterial infections, a clear chronological and pathogenetic relationship is established for SBP with 20% to 30% of patients with SBP develop HRS despite appropriate treatment and resolution of infection.<sup>
               <xref ref-type="bibr" rid="bibr32-0885066611408692">32</xref>,<xref ref-type="bibr" rid="bibr33-0885066611408692">33</xref>
            </sup> Similarly, large-volume paracentesis without albumin expansion precipitates type 1 HRS in 15% of cases, and 25% of patients presenting with acute alcoholic hepatitis eventually develop HRS.<sup>
               <xref ref-type="bibr" rid="bibr34-0885066611408692">34</xref>,<xref ref-type="bibr" rid="bibr35-0885066611408692">35</xref>
            </sup> Although AKI following gastrointestinal hemorrhage occurs more frequently in patients with cirrhosis compared to those without liver disease with similar amount of bleeding (8% vs 1%, <italic>P</italic> &lt; .05), AKI develops almost exclusively in patients with hypovolemic shock, making ATN a more plausible diagnosis.<sup>
               <xref ref-type="bibr" rid="bibr36-0885066611408692">36</xref>
            </sup>
         </p>
         <p>Why would a precipitating event lead to HRS or the progression of type 2 to the more severe type 1 HRS? Most of the above described precipitating events will lead to aggravation of the circulatory dysfunction with further stimulation of the RAAS, SNS, and worsening renal vasoconstriction.<sup>
               <xref ref-type="bibr" rid="bibr16-0885066611408692">16</xref>
            </sup> Another possible explanation is that the deterioration in renal function is secondary to deterioration in cardiac function due to either the development of septic cardiomyopathy or worsening of a latent cirrhotic cardiomyopathy.<sup>
               <xref ref-type="bibr" rid="bibr18-0885066611408692">18</xref>
            </sup> In either case, the resultant renal hypoperfusion will lead to deterioration in renal function that might not reverse to baseline values without vasoconstrictor therapy and/or liver transplantation.</p>
      </sec>
      <sec id="section5-0885066611408692">
         <title>Epidemiology</title>
         <p>Although the actual prevalence of AKI in patients with cirrhosis is unknown, AKI is reported to develop in 20% to 35% of hospitalized patients with liver cirrhosis<sup>
               <xref ref-type="bibr" rid="bibr37-0885066611408692">37</xref>,<xref ref-type="bibr" rid="bibr38-0885066611408692">38</xref>
            </sup> and is associated with higher mortality, both in the hospital and in the ambulatory settings.<sup>
               <xref ref-type="bibr" rid="bibr37-0885066611408692">37</xref>,<xref ref-type="bibr" rid="bibr39-0885066611408692">39</xref>,<xref ref-type="bibr" rid="bibr40-0885066611408692">40</xref>
            </sup> Patients with cirrhosis with ascites are at greater risk of developing AKI, and a recent study confirmed that almost 50% of patients with cirrhosis develop AKI within 41 ± 3 months of developing ascites.<sup>
               <xref ref-type="bibr" rid="bibr39-0885066611408692">39</xref>
            </sup> Hepatorenal syndrome, however, is not the most common cause of AKI in patients with cirrhosis. For example, in 1 study, HRS was the cause of AKI in only 7.6% of 129 patients with cirrhosis with ascites and AKI.<sup>
               <xref ref-type="bibr" rid="bibr39-0885066611408692">39</xref>
            </sup> In another multicenter retrospective study that included 423 patients with cirrhosis and AKI, the most common cause of AKI was either ATN (35%) or prerenal failure (32%), whereas type 1 and type 2 HRS were the cause of AKI in 20% and 6.6% of cases, respectively.<sup>
               <xref ref-type="bibr" rid="bibr41-0885066611408692">41</xref>
            </sup>
         </p>
         <p>The prevalence of HRS parallels the progression of liver disease in patients with cirrhosis. With the absence of ascites, the likelihood of deteriorating kidney function is minimal. In patients with cirrhosis with ascites, Gines et al<sup>
               <xref ref-type="bibr" rid="bibr34-0885066611408692">34</xref>
            </sup> estimated the 1-year and 5-year probability of HRS at 18% and 39%, respectively, whereas the prevalence of HRS in patients with cirrhosis having advanced liver disease waiting for liver transplantation is as high as 48%.<sup>
               <xref ref-type="bibr" rid="bibr42-0885066611408692">42</xref>
            </sup>
         </p>
      </sec>
      <sec id="section6-0885066611408692">
         <title>Natural History and Prognosis</title>
         <p>Hepatorenal syndrome is a functional renal failure without significant histological changes, and therefore is potentially reversible. However, if left untreated, intense renal vasoconstriction precipitates irreversible renal damage. This explains as to why not all cases of HRS recover kidney function following liver transplantation. Untreated type 1 HRS carries a grim prognosis, with mortality as high as 80% in 2 weeks, and only 10% of patients survive more than 3 months.<sup>
               <xref ref-type="bibr" rid="bibr25-0885066611408692">25</xref>,<xref ref-type="bibr" rid="bibr34-0885066611408692">34</xref>
            </sup> By contrast, survival of type 2 HRS patients is slightly better, with a median survival of 6 months.<sup>
               <xref ref-type="bibr" rid="bibr27-0885066611408692">27</xref>
            </sup> Model of end-stage liver disease (MELD) score is also an independent predictor of death in type 2 HRS, with the median survival of only 1 month for patients with a MELD score of 20 or more compared to 8 months in those with a MELD score &lt;20 (<italic>P</italic> &lt; .001). Interestingly, patients with type 1 HRS have very poor prognosis (median survival of 1 month), irrespective of their MELD score.<sup>
               <xref ref-type="bibr" rid="bibr43-0885066611408692">43</xref>
            </sup> A recent study has demonstrated that the 3-month survival of patients with cirrhosis having HRS is much worse than those with cirrhosis and other forms of AKI.<sup>
               <xref ref-type="bibr" rid="bibr44-0885066611408692">44</xref>
            </sup> In this study that included 562 patients with cirrhosis having AKI, 3-month survival for patients with HRS was 15% compared to 31% for patients with infection-induced AKI, 46% for hypovolemia-induced AKI, and 73% for AKI associated with evidence of parenchymal renal disease (eg proteinuria or hematuria; <italic>P</italic> &lt; .0005). Therefore, determining the etiology of AKI in patients with cirrhosis does not only determine the treatment plan but it also foretells the prognosis in these patients.</p>
      </sec>
      <sec id="section7-0885066611408692">
         <title>Treatment</title>
         <sec id="section8-0885066611408692">
            <title>Prevention</title>
            <p>Some interventions are beneficial in reducing the risk of HRS, in specific, clinical settings. For example, prophylactic antibiotic therapy in patients at high risk of SBP has proven effective in reducing HRS risk. In a study by Fernandez et al,<sup>
                  <xref ref-type="bibr" rid="bibr44-0885066611408692">44</xref>
               </sup> 68 patients with cirrhosis were randomized to receive either daily norfloxacin (n = 35) or placebo (n = 33). Daily norfloxacin reduced the 1-year probability of developing SBP from 61% to 7% (<italic>P</italic> &lt; .001) and the 1-year probability of HRS from 41% to 28% (<italic>P</italic> = .02). The beneficial effect of norfloxacin in preventing HRS is probably related to its ability to prevent bacterial translocation, suppress proinflammatory cytokines, and improve circulatory function.<sup>
                  <xref ref-type="bibr" rid="bibr45-0885066611408692">45</xref>,<xref ref-type="bibr" rid="bibr46-0885066611408692">46</xref>
               </sup> Once SBP has developed, treatment with intravenous albumin (1.5 g/kg of body weight at diagnosis followed by 1 g/kg 48 hours later) in addition to ceftriaxone reduced the incidence of HRS to 10%, compared to 33% in those who received ceftriaxone alone (<italic>P</italic> = .002).<sup>
                  <xref ref-type="bibr" rid="bibr33-0885066611408692">33</xref>
               </sup> Hospital mortality (10% vs 29%) and 3-month mortality rates (22% vs 41%) were also lower in patients receiving albumin and antibiotic compared with those who received antibiotic alone.<sup>
                  <xref ref-type="bibr" rid="bibr33-0885066611408692">33</xref>
               </sup> The mechanism by which albumin prevents HRS is incompletely understood but may be related to albumin’s positive effect on circulatory function and its antioxidant properties.<sup>
                  <xref ref-type="bibr" rid="bibr47-0885066611408692">47</xref>,<xref ref-type="bibr" rid="bibr48-0885066611408692">48</xref>
               </sup> In patients with acute alcoholic hepatitis, the administration of the TNF inhibitor pentoxifylline for 28 days or until death reduced the probability of HRS by 8% in the pentoxifylline group vs 35% in the placebo group (relative risk [RR] = 0.32, 95% confidence interval [CI] = 0.13-0.79, <italic>P</italic> = .0015) and hospital mortality by 24% vs 46% (RR = 0.59, 95% CI = 0.35-0.97, <italic>P</italic> = .037).<sup>
                  <xref ref-type="bibr" rid="bibr35-0885066611408692">35</xref>
               </sup> Following large-volume paracentesis (≥5 L), albumin is more superior than other plasma expanders in preventing postparacentesis circulatory dysfunction and renal impairment.<sup>
                  <xref ref-type="bibr" rid="bibr49-0885066611408692">49</xref>,<xref ref-type="bibr" rid="bibr50-0885066611408692">50</xref>
               </sup> Other measures of preventing HRS include avoiding nonsteroidal anti-inflammatory drugs, aminoglycoside antibiotics, and the judicious use of diuretics.</p>
         </sec>
         <sec id="section9-0885066611408692">
            <title>General Measures</title>
            <p>Patients with type 1 HRS usually require hospitalization, preferably in the intensive care unit, whereas those with type 2 HRS can be managed on an outpatient basis. Assessing the intravascular volume status using central venous access or, preferably, global end-diastolic volume index (GEDVI) is essential to guide the fluid and albumin infusion.<sup>
                  <xref ref-type="bibr" rid="bibr51-0885066611408692">51</xref>
               </sup> Although in other critically ill patients there is no clear benefit for colloid over crystalloid use for fluid resuscitation, albumin infusion is clearly beneficial in patients with cirrhosis and should be aggressively used prior to labeling patients with cirrhosis and AKI as having HRS (<xref ref-type="table" rid="table2-0885066611408692">Table 2</xref>).<sup>
                  <xref ref-type="bibr" rid="bibr52-0885066611408692">52</xref>,<xref ref-type="bibr" rid="bibr53-0885066611408692">53</xref>
               </sup> Diuretics should be stopped, and a trial of large-volume paracentesis with albumin infusion (8 g for every liter of ascitic fluid removed) is warranted in all patients with cirrhosis presenting with tense ascites and HRS. In some of these cases, the increased intra-abdominal pressure will impair renal blood flow and compress the renal veins, reducing the effective renal filtration fraction.<sup>
                  <xref ref-type="bibr" rid="bibr54-0885066611408692">54</xref>
               </sup> In 1 study, goal-directed albumin infusion to maintain a stable GEDVI following large-volume paracentesis resulted in reduction in the intra-abdominal pressure and systemic vascular resistance and an increase in cardiac index, urine output, and creatinine clearance in 19 patients with HRS admitted to the intensive care unit with tense ascites.<sup>
                  <xref ref-type="bibr" rid="bibr51-0885066611408692">51</xref>
               </sup> A similar study has also documented an increase in renal-resistive indices following paracentesis and albumin infusion in 12 HRS patients with tense ascites.<sup>
                  <xref ref-type="bibr" rid="bibr55-0885066611408692">55</xref>
               </sup>
            </p>
            <p>Associated adrenal insufficiency should be diagnosed and treated with hydrocortisone administration.<sup>
                  <xref ref-type="bibr" rid="bibr22-0885066611408692">22</xref>,<xref ref-type="bibr" rid="bibr23-0885066611408692">23</xref>
               </sup> Every effort should be made to exclude other causes of AKI and to identify and treat precipitating factors especially SBP and gastrointestinal bleeding. Special consideration should be made to nutrition as these patients are usually malnourished; however, high-protein diet may precipitate hepatic encephalopathy and aggravate the metabolic abnormalities. Low-salt diet should be reinforced in all cases and free water restriction in those who develop hyponatremia.<sup>
                  <xref ref-type="bibr" rid="bibr56-0885066611408692">56</xref>
               </sup> Once the patient is stabilized, realistic assessment of the overall patient’s prognosis and concurrent medical condition will determine future management plans. Given the dismal prognosis of patients with type 1 HRS, aggressive therapy is usually indicated only for patients waiting for liver transplant or undergoing evaluation to determine candidacy for transplantation. There are 4 therapeutic options for the patient with HRS: pharmacological treatment, transjugular intrahepatic portosystemic shunt (TIPS), renal replacement therapy (RRT), and liver transplantation.</p>
         </sec>
         <sec id="section10-0885066611408692">
            <title>Pharmacological Therapy</title>
            <p>The goals of ideal treatment for HRS must include the following: (1) reversal of renal failure, (2) prolong survival at least slightly to increase the chance of liver transplantation, and (3) have minimal side effects.</p>
            <p>Various renal vasodilator agents, including dopamine, fenoldopam, and prostaglandins, have been studied and found to be ineffective and associated with increased side effects; therefore, the use of renal vasodilators in patients with HRS has been largely abandoned.<sup>
                  <xref ref-type="bibr" rid="bibr57-0885066611408692">57</xref>
                  <xref ref-type="bibr" rid="bibr58-0885066611408692"/>
                  <xref ref-type="bibr" rid="bibr59-0885066611408692"/>–<xref ref-type="bibr" rid="bibr60-0885066611408692">60</xref>
               </sup> Based on the current knowledge of the underlying pathophysiological mechanisms, administration of vasoconstrictor agents such as vasopressin analogs and α<sub>1</sub> agonists is the best approach to managing HRS.</p>
            <p>Vasopressin analogs ornipressin and terlipressin are potent vasoconstrictors that exert their action through binding to the vasopressin (V1) receptor, which is preferentially expressed on the vascular smooth muscle cells within the splanchnic circulation. Although associated with remarkable improvement in renal function, increase in RPF, GFR, and sodium excretion in almost 50% of the treated cases, ornipressin use has largely been abandoned due to significant ischemic side effects that develop in almost 30% of the treated patients.<sup>
                  <xref ref-type="bibr" rid="bibr61-0885066611408692">61</xref>
                  <xref ref-type="bibr" rid="bibr62-0885066611408692"/>–<xref ref-type="bibr" rid="bibr63-0885066611408692">63</xref>
               </sup>
            </p>
            <p>Terlipressin is a long-acting synthetic vasopressin analog composed of 1 molecule of lysine vasopressin and 3 glycine residues. It is metabolized through exopeptidases to release small amounts of lysine vasopressin over a sustained period, allowing it to be administered by bolus injection rather than by continuous infusion.<sup>
                  <xref ref-type="bibr" rid="bibr64-0885066611408692">64</xref>
               </sup> The administration of terlipressin and albumin is associated with significant improvement in GFR, an increase in arterial pressure, near normalization of neurohormonal levels (including plasma renin activity, serum aldosterone, and norepinephrine levels), and reduction of serum creatinine in 42% to 77% of cases.<sup>
                  <xref ref-type="bibr" rid="bibr29-0885066611408692">29</xref>,<xref ref-type="bibr" rid="bibr41-0885066611408692">41</xref>,<xref ref-type="bibr" rid="bibr65-0885066611408692">65</xref>
                  <xref ref-type="bibr" rid="bibr66-0885066611408692"/>
                  <xref ref-type="bibr" rid="bibr67-0885066611408692"/>–<xref ref-type="bibr" rid="bibr68-0885066611408692">68</xref>
               </sup> Hemodynamic studies have also documented improvement in renal arterial resistive index following terlipressin infusion in 19 patients with cirrhosis and portal hypertension.<sup>
                  <xref ref-type="bibr" rid="bibr69-0885066611408692">69</xref>
               </sup> Multiple clinical studies evaluated the role of terlipressin in HRS reversal (<xref ref-type="table" rid="table4-0885066611408692">Table 4</xref>
). From these studies, terlipressin appears to have an acceptable side effect profile, with ischemic events occurring in 5% to 30% of cases, but most studies excluded patients at high risk of ischemic events (<xref ref-type="table" rid="table5-0885066611408692">Table 5</xref>
). Following completion of therapy, HRS recurred in up to 50% of cases. Factors associated with HRS recurrence are unknown, but renal function responds to the reintroduction of terlipressin.<sup>
                  <xref ref-type="bibr" rid="bibr29-0885066611408692">29</xref>
               </sup> The benefits of terlipressin also seem to extend to type 2 HRS, with a slightly better response rate and longer survival than in type 1.<sup>
                  <xref ref-type="bibr" rid="bibr65-0885066611408692">65</xref>,<xref ref-type="bibr" rid="bibr67-0885066611408692">67</xref>,<xref ref-type="bibr" rid="bibr70-0885066611408692">70</xref>
               </sup> All studies used terlipressin until serum creatinine decreased to &lt;1.5 mg/dL or for a maximum of 15 days; therefore, it is unclear whether longer duration of therapy will be of any benefit in increasing the HRS reversal rate.</p>
            <table-wrap id="table4-0885066611408692" position="float">
               <label>Table 4.</label>
               <caption>
                  <p>Summary of Some of the Studies of Terlipressin in HRS.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table4-0885066611408692" position="float" xlink:href="10.1177_0885066611408692-table4.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1">Reference</th>
                        <th colspan="1" rowspan="1">Randomized Study</th>
                        <th align="center" colspan="1" rowspan="1">Type 1 HRS</th>
                        <th align="center" colspan="1" rowspan="1">Type 2 HRS</th>
                        <th align="center" colspan="1" rowspan="1">Response Rate (%)</th>
                        <th align="center" colspan="1" rowspan="1">Adverse Events (%)</th>
                        <th align="center" colspan="1" rowspan="1">Terlipressin Dose (mg/d)</th>
                        <th align="center" colspan="1" rowspan="1">Duration of Therapy Mean (Range) in Days</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">Uriz et al.<sup>
                              <xref ref-type="bibr" rid="bibr66-0885066611408692">66</xref>
                           </sup>
                        </td>
                        <td align="center" colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">3</td>
                        <td colspan="1" rowspan="1">78</td>
                        <td colspan="1" rowspan="1">11</td>
                        <td colspan="1" rowspan="1">3-12</td>
                        <td colspan="1" rowspan="1">9 (5-15)</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Ortega et al.<sup>
                              <xref ref-type="bibr" rid="bibr65-0885066611408692">65</xref>
                           </sup>
                        </td>
                        <td align="center" colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">67</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">3-12</td>
                        <td colspan="1" rowspan="1">7 (4-14)</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Colle et al.<sup>
                              <xref ref-type="bibr" rid="bibr29-0885066611408692">29</xref>
                           </sup>
                        </td>
                        <td align="center" colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">18</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">61</td>
                        <td colspan="1" rowspan="1">NA</td>
                        <td colspan="1" rowspan="1">2-4</td>
                        <td colspan="1" rowspan="1">NA</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Halimi et al.<sup>
                              <xref ref-type="bibr" rid="bibr129-0885066611408692">129</xref>
                           </sup>
                        </td>
                        <td align="center" colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">72</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">2-12</td>
                        <td colspan="1" rowspan="1">7 (2-16)</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Moreau et al.<sup>
                              <xref ref-type="bibr" rid="bibr41-0885066611408692">41</xref>
                           </sup>
                        </td>
                        <td align="center" colspan="1" rowspan="1">No</td>
                        <td colspan="1" rowspan="1">99</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">58</td>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">3.2 ± 1.3</td>
                        <td colspan="1" rowspan="1">11 ± 12</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Solanki et al.<sup>
                              <xref ref-type="bibr" rid="bibr68-0885066611408692">68</xref>
                           </sup>
                        </td>
                        <td colspan="1" rowspan="1">Terlipressin/albumin vs placebo/albumin</td>
                        <td colspan="1" rowspan="1">24</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">42</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">2</td>
                        <td colspan="1" rowspan="1">4-15</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Sanyal et al.<sup>
                              <xref ref-type="bibr" rid="bibr71-0885066611408692">71</xref>
                           </sup>
                        </td>
                        <td colspan="1" rowspan="1">Terlipressin/albumin vs placebo/albumin</td>
                        <td colspan="1" rowspan="1">62</td>
                        <td colspan="1" rowspan="1">0</td>
                        <td colspan="1" rowspan="1">34</td>
                        <td colspan="1" rowspan="1">32 *</td>
                        <td colspan="1" rowspan="1">4-8</td>
                        <td colspan="1" rowspan="1">14</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Martin-Llahi et al.<sup>
                              <xref ref-type="bibr" rid="bibr70-0885066611408692">70</xref>
                           </sup>
                        </td>
                        <td colspan="1" rowspan="1">Terlipressin/albumin vs albumin only</td>
                        <td colspan="1" rowspan="1">17</td>
                        <td colspan="1" rowspan="1">6</td>
                        <td colspan="1" rowspan="1">43</td>
                        <td colspan="1" rowspan="1">31†</td>
                        <td colspan="1" rowspan="1">6-12</td>
                        <td colspan="1" rowspan="1">15</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Average</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">258</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">57</td>
                        <td colspan="1" rowspan="1">16</td>
                        <td colspan="1" rowspan="1">1-12</td>
                        <td colspan="1" rowspan="1">2-16</td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn3-0885066611408692">
                     <p>* Similar to placebo.</p>
                  </fn>
                  <fn id="table-fn4-0885066611408692">
                     <p>† Including arrhythmia, myocardial infarction, suspected intestinal ischemia, and arterial hypertension requiring discontinuation of therapy.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
            <table-wrap id="table5-0885066611408692" position="float">
               <label>Table 5.</label>
               <caption>
                  <p>Contraindications to Terlipressin Use.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table5-0885066611408692" position="float" xlink:href="10.1177_0885066611408692-table5.tif" xlink:type="simple"/>
               <table>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">History of coronary artery disease</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Dilated and nondilated cardiomyopathies</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Cardiac arrythmias</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Cerebrovascular disease</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Peripheral vascular disease of the lower extremities</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Arterial hypertension</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Asthma or obstructive lung disease</td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Age &gt;70 years</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
            <p>Of the studies listed in <xref ref-type="table" rid="table4-0885066611408692">Table 4</xref>, 2 recent prospective randomized studies are worth mentioning. The first is a multicenter, double-blinded study that included 112 patients with type 1 HRS randomized in 1:1 fashion to either terlipressin plus albumin or placebo plus albumin. More patients in the terlipressin arm (34% compared to 13% in the placebo arm, <italic>P</italic> = .008) achieved reversal of HRS defined as a serum creatinine of ≤1.5 mg/dL on 2 separate occasions 48 hours apart.<sup>
                  <xref ref-type="bibr" rid="bibr71-0885066611408692">71</xref>
               </sup> The most important predictor of HRS reversal was a low serum creatinine at initiation of therapy. In fact, none of the HRS cases with a serum creatinine ≥5.6 mg/dL responded to terlipressin (personal communication, Dr. Sanyal, November 2010). Although HRS reversal was associated with improvement in survival at 90 days (<italic>P</italic> = .025), this beneficial effect became less apparent at day 180 (<italic>P</italic> = .07). Also, the overall and transplantation-free survival was similar between study groups (<italic>P</italic> = .84).<sup>
                  <xref ref-type="bibr" rid="bibr71-0885066611408692">71</xref>
               </sup> The second study intended to investigate whether the effect of terlipressin infusion on HRS reversal is independent of albumin, as earlier studies suggested that albumin alone is beneficial in improving kidney function in HRS.<sup>
                  <xref ref-type="bibr" rid="bibr72-0885066611408692">72</xref>,<xref ref-type="bibr" rid="bibr73-0885066611408692">73</xref>
               </sup> This study included 46 patients with either type 1 or type 2 HRS randomized to receive either terlipressin and albumin or albumin alone.<sup>
                  <xref ref-type="bibr" rid="bibr70-0885066611408692">70</xref>
               </sup> There was significant difference in favor of terlipressin in the likelihood of HRS reversal (44% in study group vs 8.7% in the control group, <italic>P</italic> = .017) but 3-month survival was not different between those who did or did not receive terlipressin (27% in the terlipressin arm vs 19% in the albumin arm, <italic>P</italic> = .7).<sup>
                  <xref ref-type="bibr" rid="bibr70-0885066611408692">70</xref>
               </sup> Again, a lower baseline serum creatinine level at initiation of therapy predicted a favorable response to terlipressin, suggesting that earlier initiation of therapy might confer the best probability of improvement in kidney function. Other predictors of favorable response to terlipressin include young age and a Child-Pugh score of &lt;13.<sup>
                  <xref ref-type="bibr" rid="bibr29-0885066611408692">29</xref>,<xref ref-type="bibr" rid="bibr41-0885066611408692">41</xref>
               </sup>
            </p>
            <p>Terlipressin is unavailable in many countries, including the United States. Cost of terlipressin might also be prohibitive. Unlike terlipressin, α<sub>1</sub> adrenergic receptor agonists such as midodrine and norepinephrine are readily available and have been shown to be effective in the treatment of HRS. When given as monotherapy, oral midodrine slightly improved systemic hemodynamics but failed to improve renal function in 8 type 2 HRS cases.<sup>
                  <xref ref-type="bibr" rid="bibr74-0885066611408692">74</xref>,<xref ref-type="bibr" rid="bibr75-0885066611408692">75</xref>
               </sup> However, when combined with the glucagon inhibitor octreotide (glucagon mediates splanchnic vasodilatation) and in combination with albumin infusion, a significant improvement in renal function and survival were observed. Two nonrandomized studies evaluated the efficacy of oral midodrine and octreotide combination on HRS reversal.<sup>
                  <xref ref-type="bibr" rid="bibr30-0885066611408692">30</xref>,<xref ref-type="bibr" rid="bibr76-0885066611408692">76</xref>
               </sup> The first study was a prospective trial that included 5 patients with type 1 HRS. In this study, the dose of midodrine was increased from 7.5 mg 3 times daily to 12.5 mg 3 times daily, and the dose of subcutaneous octreotide was titrated from 100 μg 3 times daily to 200 μg 3 times daily if the central venous pressure did not increase or the plasma renin activity was not reduced, compared to baseline values on day 3 of therapy. After 20 days, the mean arterial pressure increased, plasma renin activity decreased, and all patients achieved reversal of HRS defined as a serum creatinine less than 2mg/dL.<sup>
                  <xref ref-type="bibr" rid="bibr76-0885066611408692">76</xref>
               </sup> In the second study, continuous intravenous octreotide infusion (25 μg/h) and fixed dose oral midodrine (2.5 mg/d) were used in 14 patients with type 1 HRS. Therapy was administered until serum creatinine was &lt;1.5 mg/dL for 3 days or for a total of 15 days. Hepatorenal syndrome reversal was achieved in 70% of cases. In both studies, no significant treatment-related side effects were reported and therapy was well tolerated.<sup>
                  <xref ref-type="bibr" rid="bibr30-0885066611408692">30</xref>
               </sup>
            </p>
            <p>It is important to mention that midodrine is a prodrug that is metabolized in the liver into an active metabolite, desglymidodrine, which is later eliminated in the urine. The pharmacokinetics of midodrine and desglymidodrine in patients with HRS have not been studied and deserve further research. Also, it is still unclear whether terlipressin is superior to octreotide and midodrine in reversing HRS. One study suggested that terlipressin-treated patients have a higher HRS recovery rate, longer survival, and are more likely to receive a liver transplant, but this study was nonrandomized and the results could have been affected by selection bias.<sup>
                  <xref ref-type="bibr" rid="bibr77-0885066611408692">77</xref>
               </sup> Finally, the Food and Drug Administration (FDA) is considering withdrawing oral midodrine from the markets due to the lack of long-term benefit data, mainly in patients with orthostatic hypotension; however, doing so would limit the treatment options for patients with HRS who do not have access to terlipressin.</p>
            <p>Finally, the effect of continuous norepinephrine infusion (starting at 0.5 mg/h and titrated to achieve 10 mm Hg increase in mean blood pressure and/or increase in urine output by &gt;200 mL/4 h) in association with albumin and furosemide on HRS reversal was studied in 12 type 1 HRS patients.<sup>
                  <xref ref-type="bibr" rid="bibr78-0885066611408692">78</xref>
               </sup> Norepinephrine was given, either until serum creatinine decreased &lt;1.5 mg/dL or for a maximum of 15 days. The mean norepinephrine dose given was 0.8 mg/h for a mean duration of 10 days. Of the 12 patients, 10 (83%) achieved HRS reversal (terlipressin had previously failed in 2). Ischemic episodes were observed in 2 (17%) patients.<sup>
                  <xref ref-type="bibr" rid="bibr78-0885066611408692">78</xref>
               </sup> Improvement of kidney function was associated with improvement in patient’s survival, and 4 of the responders did not require liver transplantation 6 to 18 months after recovery of renal function.<sup>
                  <xref ref-type="bibr" rid="bibr78-0885066611408692">78</xref>
               </sup> In a recent meta-analysis, terlipressin and norepinephrine were equivalent in terms of side effect profile and probability of HRS reversal.<sup>
                  <xref ref-type="bibr" rid="bibr79-0885066611408692">79</xref>
               </sup>
            </p>
         </sec>
         <sec id="section11-0885066611408692">
            <title>Transjugular Intrahepatic Portosystemic Shunt</title>
            <p>The association between the reduction of portal pressure induced by TIPS insertion and beneficial changes in neurohumoral factors and renal function in patients with cirrhosis and refractory ascites, a forerunner of HRS, is well documented.<sup>
                  <xref ref-type="bibr" rid="bibr80-0885066611408692">80</xref>
                  <xref ref-type="bibr" rid="bibr81-0885066611408692"/>
                  <xref ref-type="bibr" rid="bibr82-0885066611408692"/>
                  <xref ref-type="bibr" rid="bibr83-0885066611408692"/>–<xref ref-type="bibr" rid="bibr84-0885066611408692">84</xref>
               </sup> Guevara et al prospectively investigated the biochemical, hemodynamic, and neurohumoral changes following TIPS insertion in 7 type 1 HRS cases.<sup>
                  <xref ref-type="bibr" rid="bibr85-0885066611408692">85</xref>
               </sup> One month after TIPS, renal function improved in 6 patients (86%), with significant reduction in serum creatinine and increase in urine volume. These clinical changes paralleled amelioration in renal hemodynamics and reduction in the plasma levels of different mediators of vasoconstriction. Patient’s survival ranged from 10 to 570 days with 30 days survival achieved in 5 patients (71%).<sup>
                  <xref ref-type="bibr" rid="bibr85-0885066611408692">85</xref>
               </sup> Another prospective nonrandomized study evaluated the effect of TIPS on long-term outcome of 31 patients with type 1 or type 2 HRS who are not candidates for liver transplantation.<sup>
                  <xref ref-type="bibr" rid="bibr86-0885066611408692">86</xref>
               </sup> After TIPS, the 3, 6, 12, and 18 months survival were 81%, 71%, 48%, and 35%, respectively. Importantly, survival at 10 weeks of type 1 HRS patients managed with TIPS was 53%, a significant improvement compared to historical cases.<sup>
                  <xref ref-type="bibr" rid="bibr34-0885066611408692">34</xref>
               </sup> Of the 7 dialysis-dependent cases, 4 discontinued dialysis following TIPS insertion, and liver transplantation was performed in 2 cases 7 and 24 months after TIPS, when the medical condition precluding transplantation has abated.<sup>
                  <xref ref-type="bibr" rid="bibr86-0885066611408692">86</xref>
               </sup> An important observation from these 2 studies is the slow and delayed recovery of renal function following TIPS (within 2-4 weeks), unlike vasoconstrictor therapy, in which responders have faster recovery of renal function (1-2 weeks). It is important to mention that all patients with advanced cirrhosis (bilirubin &gt;15 mg/dL, Child-Pugh score &gt;12, or history of hepatic encephalopathy) were excluded from these 2 studies, limiting TIPS as a viable treatment option in many patients with HRS. Nevertheless, the results of these studies demonstrate that there is occasionally a group of patients with HRS in whom TIPS insertion might prolong survival long enough either to receive a liver transplant or, if they are not candidates, to stay off dialysis.</p>
         </sec>
         <sec id="section12-0885066611408692">
            <title>Combination Therapy</title>
            <p>In all, 14 cirrhotic patients with type 1 HRS were treated with oral midodrine, octreotide, and albumin, followed by TIPS insertion in 5 of the 10 patients who responded to vasoconstrictor therapy and were at low risk of hepatic encephalopathy.<sup>
                  <xref ref-type="bibr" rid="bibr30-0885066611408692">30</xref>
               </sup> All 5 patients who received combination therapy were alive 6 to 30 months following TIPS, with only 1 patient requiring liver transplantation 13 months later. On the other hand, responders to vasoconstrictors who did not receive TIPS either died (3 patients) or required a liver transplantation (2 patients). Another study of combination therapy that included 11 type 2 HRS cases managed with sequential terlipressin and TIPS showed further improvement in kidney function following TIPS insertion.<sup>
                  <xref ref-type="bibr" rid="bibr67-0885066611408692">67</xref>
               </sup> However, due to the small number of patients and the fact that many patients with advanced cirrhosis are inherently not candidates for TIPS, it is difficult to draw firm conclusions on the exact role of combination therapy in the treatment of HRS.</p>
         </sec>
         <sec id="section13-0885066611408692">
            <title>Effect of Therapy on Patients' Survival</title>
            <p>Vasoconstrictors may improve renal function in HRS, but their effect on mortality is unclear. In a recent study, Gluud and colleagues<sup>
                  <xref ref-type="bibr" rid="bibr87-0885066611408692">87</xref>
               </sup> performed a systematic review of 10 trials comprising 376 patients with either type 1 or type 2 HRS who received terlipressin alone or with albumin, octreotide plus albumin, or norepinephrine plus albumin. Mortality was the primary outcome measure. Overall, vasoconstrictors used alone or with albumin reduced mortality compared with no intervention or albumin alone (74% vs 58%, RR: 0.82, 95% CI: 0.70-0.96). In subgroup analyses, the improved survival was apparent at day 15 of therapy (RR: 0.60, 95% CI: 0.37-0.97) but not at 30, 60, 90, and 180 days. When compared to albumin alone, terlipressin plus albumin conferred a survival advantage in type 1 but not in type 2 HRS. There was no significant difference between the type of vasoconstrictor and the patient’s survival.<sup>
                  <xref ref-type="bibr" rid="bibr87-0885066611408692">87</xref>
               </sup> Despite the lack of clear survival advantage, the limited number of days gained with vasoconstrictor therapy might be crucial to allow for liver transplantation. Also, current evidence indicates that posttransplant outcomes in patients with HRS who responded to pretransplant vasoconstrictors are similar to patients with normal renal function who received transplant.<sup>
                  <xref ref-type="bibr" rid="bibr88-0885066611408692">88</xref>
               </sup> Therefore, all attempts to improve kidney function prior to liver transplantation should be made.</p>
            <p>
               <xref ref-type="table" rid="table6-0885066611408692">Table 6</xref>
summarizes the 30- and 90-day survival of untreated patients with HRS and those who received therapy with different vasoconstrictor agents, TIPS, or a combination of vasoconstrictor and TIPS. The important observations are (1) compared to no treatment, the 30-day survival of HRS did improve with different treatment modalities, and (2) 90-day survival of HRS remains to be dismal, irrespective of the treatment offered.</p>
            <table-wrap id="table6-0885066611408692" position="float">
               <label>Table 6.</label>
               <caption>
                  <p>Thirty-day and 90-day Survival Following Treatment of HRS by Treatment Modality.</p>
               </caption>
               <graphic alt-version="no" alternate-form-of="table6-0885066611408692" position="float" xlink:href="10.1177_0885066611408692-table6.tif" xlink:type="simple"/>
               <table>
                  <thead>
                     <tr>
                        <th colspan="1" rowspan="1"> </th>
                        <th colspan="1" rowspan="1">
                           <bold>Number of Patients</bold>
                        </th>
                        <th colspan="1" rowspan="1">
                           <bold>30-day</bold> Survival (%)</th>
                        <th colspan="1" rowspan="1">
                           <bold>90-day</bold> Survival (%)</th>
                        <th colspan="1" rowspan="1">
                           <bold>Reference</bold>
                        </th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td colspan="1" rowspan="1">No treatment</td>
                        <td colspan="1" rowspan="1">
</td>
                        <td colspan="1" rowspan="1">25</td>
                        <td colspan="1" rowspan="1">10</td>
                        <td colspan="1" rowspan="1">Gines et al.<sup>
                              <xref ref-type="bibr" rid="bibr34-0885066611408692">34</xref>
                           </sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Octreotide + midodrine</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">80</td>
                        <td colspan="1" rowspan="1">33</td>
                        <td colspan="1" rowspan="1">Angeli et al.<sup>
                              <xref ref-type="bibr" rid="bibr76-0885066611408692">76</xref>
                           </sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">NE</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">50</td>
                        <td colspan="1" rowspan="1">NA</td>
                        <td colspan="1" rowspan="1">Duvoux et al.<sup>
                              <xref ref-type="bibr" rid="bibr78-0885066611408692">78</xref>
                           </sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="3">Terlipressin</td>
                        <td colspan="1" rowspan="1">21</td>
                        <td colspan="1" rowspan="1">61</td>
                        <td colspan="1" rowspan="1">12</td>
                        <td colspan="1" rowspan="1">Ortega et al.<sup>
                              <xref ref-type="bibr" rid="bibr65-0885066611408692">65</xref>
                           </sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">99</td>
                        <td colspan="1" rowspan="1">40</td>
                        <td colspan="1" rowspan="1">22</td>
                        <td colspan="1" rowspan="1">Moreau et al.<sup>
                              <xref ref-type="bibr" rid="bibr41-0885066611408692">41</xref>
                           </sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">23</td>
                        <td colspan="1" rowspan="1">NA</td>
                        <td colspan="1" rowspan="1">27</td>
                        <td colspan="1" rowspan="1">Martin-Llahi et al.<sup>
                              <xref ref-type="bibr" rid="bibr70-0885066611408692">70</xref>
                           </sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="2">TIPS</td>
                        <td colspan="1" rowspan="1">7</td>
                        <td colspan="1" rowspan="1">71</td>
                        <td colspan="1" rowspan="1">42</td>
                        <td colspan="1" rowspan="1">Guevara et al.<sup>
                              <xref ref-type="bibr" rid="bibr85-0885066611408692">85</xref>*</sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">14</td>
                        <td colspan="1" rowspan="1">81</td>
                        <td colspan="1" rowspan="1">64</td>
                        <td colspan="1" rowspan="1">Brensing et al.<sup>
                              <xref ref-type="bibr" rid="bibr86-0885066611408692">86</xref>*</sup>
                        </td>
                     </tr>
                     <tr>
                        <td colspan="1" rowspan="1">Vasoconstrictor + TIPS</td>
                        <td colspan="1" rowspan="1">5</td>
                        <td colspan="1" rowspan="1">100</td>
                        <td colspan="1" rowspan="1">100</td>
                        <td colspan="1" rowspan="1">Wong et al.<sup>
                              <xref ref-type="bibr" rid="bibr30-0885066611408692">30</xref>*</sup>
                        </td>
                     </tr>
                  </tbody>
               </table>
               <table-wrap-foot>
                  <fn id="table-fn5-0885066611408692">
                     <p>NE: norepinephrine; TIPS: transjugular intrahepatic protosystemic shunt; NA: not available.</p>
                  </fn>
                  <fn id="table-fn6-0885066611408692">
                     <p>* Patients with advanced cirrhosis were not candidates for TIPS insertion.</p>
                  </fn>
               </table-wrap-foot>
            </table-wrap>
         </sec>
      </sec>
      <sec id="section14-0885066611408692">
         <title>Renal Replacement Therapy</title>
         <sec id="section15-0885066611408692">
            <title>Pretransplant RRT</title>
            <p>For those waiting for a liver transplant, who did not respond to vasoconstrictors or developed volume overload, intractable metabolic acidosis, or hyperkalemia, RRT may be a reasonable option as a bridge to transplantation. Patients with HRS often manifest complications of advanced liver cell failure including encephalopathy, hypotension, and coagulopathy, which complicates the decision to initiate RRT especially since early studies have found that initiation of RRT was associated with increased risk of hemorrhage and hypotension, which directly contributed to mortality in some cases.<sup>
                  <xref ref-type="bibr" rid="bibr89-0885066611408692">89</xref>,<xref ref-type="bibr" rid="bibr90-0885066611408692">90</xref>
               </sup> However, mortality is even higher in patients with HRS not receiving RRT. In a retrospective study by Keller et al,<sup>
                  <xref ref-type="bibr" rid="bibr91-0885066611408692">91</xref>
               </sup> 7 (44%) of 16 cases on RRT survived to transplantation compared to only 1 (10%) of the 10 who did not receive dialysis. This improved patient survival was incurred at the cost of increased hospital stay with 33% of the survival days gained being spent in the hospital.<sup>
                  <xref ref-type="bibr" rid="bibr92-0885066611408692">92</xref>
               </sup> Therefore, in patients with HRS who are waiting for a liver transplant, RRT is justifiable as a bridge to transplantation but is associated with an increase in morbidity and mortality. However, initiation of RRT is controversial in patients with HRS who are not candidates for liver transplantation due to their dismal chance of survival without transplantation and the high morbidity and mortality associated with RRT. In these patients, the decision to initiate RRT may be considered futile and should be individualized.</p>
            <p>Predictors of mortality following RRT initiation have been studied in 82 cirrhotic patients with AKI, 26 of them with HRS. In all, 46% received intermittent hemodialysis (HD), whereas the remaining group received continuous RRT (CRRT). The relative risk of dying following RRT initiation was increased by 8.2-fold in patients with thrombocytopenia &lt;100/nL, by 3.9-fold in those with hepatic encephalopathy and by 2.8-fold in patients with malignancy. Importantly, the etiology of renal failure, whether related to HRS or not, did not affect survival.<sup>
                  <xref ref-type="bibr" rid="bibr91-0885066611408692">91</xref>
               </sup>
            </p>
            <p>There is still controversy regarding the best modality of RRT in orthotopic liver transplant (OLT) candidates. Davenport et al and Detry et al demonstrated that CRRT is better tolerated than intermittent HD in patients with liver failure as evidenced by better cardiovascular stability, gradual correction of hyponatremia, and less fluctuation in intracranial pressure.<sup>
                  <xref ref-type="bibr" rid="bibr93-0885066611408692">93</xref>
                  <xref ref-type="bibr" rid="bibr94-0885066611408692"/>
                  <xref ref-type="bibr" rid="bibr95-0885066611408692"/>–<xref ref-type="bibr" rid="bibr96-0885066611408692">96</xref>
               </sup> Furthermore, CRRT has the potential advantage of removing inflammatory cytokines including TNF-α and interleukin 6, both have been implicated in the development of AKI and HRS and the exacerbation of hepatic injury.<sup>
                  <xref ref-type="bibr" rid="bibr16-0885066611408692">16</xref>,<xref ref-type="bibr" rid="bibr35-0885066611408692">35</xref>,<xref ref-type="bibr" rid="bibr97-0885066611408692">97</xref>
                  <xref ref-type="bibr" rid="bibr98-0885066611408692"/>–<xref ref-type="bibr" rid="bibr99-0885066611408692">99</xref>
               </sup> Despite these presumed advantages, in a prospective study by Witzke et al, CRRT did not confer a survival benefit in 30 patients with HRS waiting for liver transplantation.<sup>
                  <xref ref-type="bibr" rid="bibr100-0885066611408692">100</xref>
               </sup> In this study, cases were subjected to either CRRT if they were mechanically ventilated or HD if they were not. Eight cases (53%) treated with HD survived for 30 days, whereas none of the CRRT patients survived for the same duration. At 1 year, only 3 were still alive. All received either liver transplantation (2 patients) or combined liver-kidney transplantation (1 patient). None required posttransplant HD. The author concluded that CRRT in patients with HRS on mechanical ventilation is futile.<sup>
                  <xref ref-type="bibr" rid="bibr100-0885066611408692">100</xref>
               </sup> In contrast to this experience, the group from Baylor reported on their experience in patients undergoing RRT before liver transplantation in 2 separate time periods.<sup>
                  <xref ref-type="bibr" rid="bibr101-0885066611408692">101</xref>
               </sup> From 1985 to 1995, 10 patients received preoperative RRT (all HD), and their 1-year survival posttransplant was 89.5%. From 1996 to 1999, a total of 19 patients also received preoperative RRT. One had HD, and 18, CRRT. The 1-year patient survival in this group was lower at 73.6%, possibly reflecting the more serious nature of their illness. In another study of 102 cirrhotic patients with AKI requiring RRT, 48% of them with HRS who were awaiting liver transplantation showed increased mortality for those maintained on CRRT compared to HD (78% vs 50%, <italic>P</italic> = .02; <xref ref-type="fig" rid="fig3-0885066611408692">Figure 3</xref>
).<sup>
                  <xref ref-type="bibr" rid="bibr42-0885066611408692">42</xref>
               </sup> Nevertheless, those who received CRRT had a higher APACHE II score, lower blood pressure, and were more likely to be on vasopressors and mechanical ventilation.<sup>
                  <xref ref-type="bibr" rid="bibr42-0885066611408692">42</xref>
               </sup> On a multivariate logistic model, a high mean arterial pressure, but not duration of RRT, was associated with lower risk of mortality (OR = 0.97, <italic>P</italic> = .03). Approximately, half of the patients died in the first 7 days after initiating RRT, suggesting that these patients were seriously ill and would have died regardless of RRT initiation. The authors concluded that RRT is still justifiable in acute renal failure and called for early liver transplantation in these patients, especially since the high mortality rate is a reflection of the severity of illness and is comparable to similarly ill noncirrhotic patients with AKI.<sup>
                  <xref ref-type="bibr" rid="bibr42-0885066611408692">42</xref>
               </sup>
            </p>
            <fig id="fig3-0885066611408692" position="float">
               <label>Figure 3.</label>
               <caption>
                  <p>Survival of liver transplant candidates with acute renal failure receiving different modalities of renal replacement therapy (RRT). <italic>P</italic> value is calculated for comparing CRRT versus HD. CRRT, continuous RRT; HD, intermittent hemodialysis; ALL, all patients. Adapted with permission from Wong et al.<sup>
                        <xref ref-type="bibr" rid="bibr42-0885066611408692">42</xref>
                     </sup>
                  </p>
               </caption>
               <graphic alt-version="no" position="float" xlink:href="10.1177_0885066611408692-fig3.tif" xlink:type="simple"/>
            </fig>
            <p>One drawback of CRRT is the need for continuous systemic anticoagulation, which might increase the risk of bleeding; however, patients with cirrhosis are often coagulopathic, and anticoagulation may be safely avoided. Other alternatives include regional citrate or regional heparin/protamine anticoagulation; both have been used in patients with cirrhosis and provided filter life span similar to those obtained using systemic anticoagulation.<sup>
                  <xref ref-type="bibr" rid="bibr102-0885066611408692">102</xref>
               </sup> However, caution should be exercised with citrate anticoagulation, as hepatic citrate metabolism is impaired in patients with cirrhosis increasing the risk of citrate toxicity.<sup>
                  <xref ref-type="bibr" rid="bibr103-0885066611408692">103</xref>
               </sup>
            </p>
            <p>Hence, although the best modality of RRT in HRS is not well defined, OLT candidates in need of RRT can be managed with either HD or CRRT before transplantation with similar outcomes. The choice of best modality is dictated by hemodynamic stability and severity of illness and should be tailored to individual patients. One clear indication for CRRT is in patients with fulminant hepatic failure and increased intracranial tension due to the adverse effect of intermittent HD on intracranial pressure.<sup>
                  <xref ref-type="bibr" rid="bibr95-0885066611408692">95</xref>
               </sup>
            </p>
            <p>The ultimate dialysis dose and timing for RRT initiation have not been studied in cirrhotic patients with HRS, but data can be inferred from other studies of AKI in critically ill patients, which suggest that early RRT initiation and maintenance of negative fluid balance improve patient survival.<sup>
                  <xref ref-type="bibr" rid="bibr104-0885066611408692">104</xref>,<xref ref-type="bibr" rid="bibr105-0885066611408692">105</xref>
               </sup> Two recent randomized studies that included a large number of critically ill patients with AKI (many of them with concomitant liver cell failure) showed no clear benefit of higher dialysis dose on hospital mortality or the probability of renal function recovery.<sup>
                  <xref ref-type="bibr" rid="bibr106-0885066611408692">106</xref>,<xref ref-type="bibr" rid="bibr107-0885066611408692">107</xref>
               </sup> However, other studies demonstrated an improvement in gas exchange, lower norepinephrine dose, earlier weaning from mechanical ventilation, shorter ICU stay, and better survival in septic patients with AKI who received early high-dose isovolemic hemofitration (45 mL/kg per h for 6 hours), followed by conventional CRRT at 20 mL/kg per h, compared to a similar group of patients who received conventional dose CRRT.<sup>
                  <xref ref-type="bibr" rid="bibr108-0885066611408692">108</xref>
               </sup> Therefore, it remains unclear whether critically ill patients with HRS will benefit from higher RRT dose. A randomized study specifically addressing this question is needed.</p>
            <p>The molecular adsorbent recirculating system (MARS) is an albumin-based form of RRT that combines a conventional CRRT circuit and albumin-enriched dialysate that is then regenerated by passage through a charcoal and ion exchange cartridge. The assumption is that, by removing albumin-bound toxins (eg bile acids and nitric oxide) and water-soluble cytokines (TNF-α and interleukin 6, both have been implicated in HRS pathogenesis), liver function will stabilize and end-organ damage will improve.<sup>
                  <xref ref-type="bibr" rid="bibr109-0885066611408692">109</xref>
                  <xref ref-type="bibr" rid="bibr110-0885066611408692"/>–<xref ref-type="bibr" rid="bibr111-0885066611408692">111</xref>
               </sup> Although studies have demonstrated improved survival with MARS compared to conventional CRRT, the overall survival is still low, with 7-day survival of 37% and 30-day survival of 25%.<sup>
                  <xref ref-type="bibr" rid="bibr109-0885066611408692">109</xref>,<xref ref-type="bibr" rid="bibr112-0885066611408692">112</xref>
               </sup> Other albumin-based dialysis techniques include single-pass albumin dialysis which can be performed using a standard CRRT circuit and fractionated plasma separation, adsorption, and dialysis (Prometheus system).<sup>
                  <xref ref-type="bibr" rid="bibr113-0885066611408692">113</xref>
               </sup> Molecular adsorbent recirculating system is currently approved by the Food and Drug Administration (FDA) for the treatment of drug overdose but not for HRS while Prometheus system is not FDA approved.</p>
         </sec>
         <sec id="section16-0885066611408692">
            <title>Intraoperative RRT</title>
            <p>Intraoperative complications, including hemodynamic instability and hyperkalemia, are more prevalent in patients with HRS undergoing liver transplantation. Derek et al<sup>
                  <xref ref-type="bibr" rid="bibr114-0885066611408692">114</xref>
               </sup> described their experience with intraoperative CRRT in 41 patients at the time of liver transplantation. Indications for the procedure were preoperative CRRT in almost 50% of the cases; hyperkalemia, dysnatremia, and metabolic acidosis in the rest of the group. Despite the presence of elevated international normalized ratio (INR) in all the patients, filter circuit clotting occurred in 40% of the cases. However, heparin or regional citrate anticoagulation was not used except in 3 patients for fear of bleeding diathesis. Nevertheless, CRRT was administered for almost 50% of the operative time, and filter clotting did not affect the duration of CRRT. This study demonstrates that intraoperative CRRT is feasible and useful in providing negative or even fluid balance, despite the large number of blood transfusions in this cohort.</p>
         </sec>
         <sec id="section17-0885066611408692">
            <title>Liver Transplantation</title>
            <p>Orthotopic liver transplant is the treatment of choice for patients with HRS. Indeed, subsequent to OLT, renal sodium excretion and hemodynamic abnormalities normalize within 1 month and renal-resistive indices decreases to normal values over the first posttransplant year.<sup>
                  <xref ref-type="bibr" rid="bibr115-0885066611408692">115</xref>,<xref ref-type="bibr" rid="bibr116-0885066611408692">116</xref>
               </sup> Survival of type 2 HRS patients is sufficiently prolonged enabling them to receive a liver transplant; however, the clinical applicability of transplantation in patients with type 1 HRS is limited by their shortened survival expectancy and long waiting times. Not all cases of HRS will recover kidney function following OLT.<sup>
                  <xref ref-type="bibr" rid="bibr117-0885066611408692">117</xref>,<xref ref-type="bibr" rid="bibr118-0885066611408692">118</xref>
               </sup> In 1 study, only 58% of HRS cases recovered kidney function 4 to 110 days after OLT.<sup>
                  <xref ref-type="bibr" rid="bibr117-0885066611408692">117</xref>
               </sup> Predictors of renal recovery included younger recipient age, nonalcoholic liver disease, and low bilirubin level at day 7 posttransplantation. There was a trend for better renal recovery with younger donor age, implying that marginal livers should be avoided in patients with HRS.<sup>
                  <xref ref-type="bibr" rid="bibr117-0885066611408692">117</xref>
               </sup>
            </p>
            <p>Patients with HRS who undergo transplantation have a lower probability of postoperative survival and a higher probability of developing postoperative complications than those without HRS. In 2 studies by Gonwa et al.,<sup>
                  <xref ref-type="bibr" rid="bibr119-0885066611408692">119</xref>,<xref ref-type="bibr" rid="bibr120-0885066611408692">120</xref>
               </sup> although the 2-year patient-and-graft survival was similar in those with or without HRS, the actuarial 5-year patient-and-graft survival rates were decreased in those with HRS. Posttransplantation, patients with HRS were sicker, required longer hospitalizations, prolonged ICU stays, and more dialysis treatments. At 6 weeks following OLT, 10% of the patients with HRS were still in need of RRT.<sup>
                  <xref ref-type="bibr" rid="bibr119-0885066611408692">119</xref>,<xref ref-type="bibr" rid="bibr121-0885066611408692">121</xref>
               </sup> The risk of end-stage renal disease (ESRD) is also higher in the patients with HRS compared to those with normal kidney function at the time of OLT (7% vs 2%).<sup>
                  <xref ref-type="bibr" rid="bibr119-0885066611408692">119</xref>
               </sup>
            </p>
            <p>In an attempt to limit posttransplant complications, another approach is to provide simultaneous liver-kidney transplantation (SLK). Indeed, since the introduction of the MELD score to guide liver allocation in the United States, the number of SLK transplants has dramatically increased, with associated lower survival compared to the pre-MELD era.<sup>
                  <xref ref-type="bibr" rid="bibr122-0885066611408692">122</xref>
                  <xref ref-type="bibr" rid="bibr123-0885066611408692"/>–<xref ref-type="bibr" rid="bibr124-0885066611408692">124</xref>
               </sup> In general, there is no survival advantage of SLK compared to OLT in patients with HRS.<sup>
                  <xref ref-type="bibr" rid="bibr121-0885066611408692">121</xref>,<xref ref-type="bibr" rid="bibr125-0885066611408692">125</xref>
               </sup> The only exception may be patients with HRS who have been on RRT for more than 8 weeks, as previous studies have suggested a low probability of renal function recovery in this group of patients.<sup>
                  <xref ref-type="bibr" rid="bibr121-0885066611408692">121</xref>
               </sup>
            </p>
            <p>Another approach is to offer kidney after liver (KAL) transplantation to patients with HRS who remain on RRT for 60 days following OLT.<sup>
                  <xref ref-type="bibr" rid="bibr118-0885066611408692">118</xref>
               </sup> Although prospective studies are lacking, observational studies suggested a lower renal half-life with this approach.<sup>
                  <xref ref-type="bibr" rid="bibr126-0885066611408692">126</xref>
               </sup>
            </p>
            <p>Our approach has been to provide OLT in the majority of HRS patients, with the exception of those who have been on RRT for 8 weeks or more. In cases where the etiology of renal failure is unclear, or if there are overlapping features of chronic kidney disease (proteinuria, hematuria, etc) and HRS, we rely on histological information to direct the transplant options.<sup>
                  <xref ref-type="bibr" rid="bibr127-0885066611408692">127</xref>
               </sup> In our hands, percutaneous kidney biopsy has been providing adequate tissue for analysis with acceptable complication profile. Other centers have been utilizing transjugular renal biopsies.<sup>
                  <xref ref-type="bibr" rid="bibr128-0885066611408692">128</xref>
               </sup> For those not on RRT, we try to reverse HRS with vasoconstrictor therapy in an attempt to improve posttransplant outcomes as previously described.<sup>
                  <xref ref-type="bibr" rid="bibr43-0885066611408692">43</xref>,<xref ref-type="bibr" rid="bibr88-0885066611408692">88</xref>
               </sup>
            </p>
         </sec>
      </sec>
      <sec id="section18-0885066611408692">
         <title>Conclusions and Future Directions</title>
         <p>In summary, HRS is associated with increased morbidity and mortality in patients with cirrhosis and has a negative impact on postliver transplant outcomes. Hepatorenal syndrome can be reversed with pharmacotherapy in more than 50% of patients, but improvement in kidney function translates into improvement in short-term survival only, with dismal long-term survival without liver transplantation. Nevertheless, every attempt to achieve HRS reversal should be made, as HRS reversal has been associated with improvement in post-liver transplant outcomes. The best therapeutic intervention, including dialysis modality, should be tailored according to patient candidacy for liver transplantation, comorbid conditions, and hemodynamic status. Simultaneous liver-kidney transplantation is generally not indicated in patients with HRS unless they have been on RRT for 8 weeks or more. Kidney biopsy might be helpful, both in differentiating HRS from other causes of AKI and guiding the decision of liver vs SLK transplantation in selected cases.</p>
      </sec>
   </body>
   <back>
      <fn-group>
         <fn fn-type="conflict" id="fn1-0885066611408692">
            <label>Declaration of Conflicting Interests</label>
            <p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
         </fn>
         <fn fn-type="financial-disclosure" id="fn2-0885066611408692">
            <label>Funding</label>
            <p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
         </fn>
      </fn-group>
      <ref-list>
         <title>References</title>
         <ref id="bibr1-0885066611408692">
            <label>1</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Koppel</surname>
                     <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Coburn</surname>
                     <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mims</surname>
                     <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Goldstein</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Boyle</surname>
                     <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rubini</surname>
                     <given-names>ME</given-names>
                  </name>
               </person-group>. <article-title>Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease</article-title>. <source>N Engl J Med</source>. <year>Jun 19 1969</year>;<volume>280</volume>(<issue>25</issue>):<fpage>1367</fpage>–<lpage>1371</lpage>.</citation>
         </ref>
         <ref id="bibr2-0885066611408692">
            <label>2</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Iwatsuki</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Popovtzer</surname>
                     <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Corman</surname>
                     <given-names>JL</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Recovery from “hepatorenal syndrome” after orthotopic liver transplantation</article-title>. <source>N Engl J Med</source>. <year>Nov 29 1973</year>;<volume>289</volume>(<issue>22</issue>):<fpage>1155</fpage>–<lpage>1159</lpage>.</citation>
         </ref>
         <ref id="bibr3-0885066611408692">
            <label>3</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Vesin</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>[Functional renal insufficiency in cirrhotics. Course. Mechanism. Treatment]</article-title>. <source>Arch Fr Mal App Dig</source>. <year>1972</year>;<volume>61</volume>(<issue>12</issue>):<fpage>775</fpage>–<lpage>786</lpage>.</citation>
         </ref>
         <ref id="bibr4-0885066611408692">
            <label>4</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Schrier</surname>
                     <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bernardi</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Epstein</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Henriksen</surname>
                     <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rodes</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis</article-title>. <source>Hepatology</source>. <year>Sep-Oct 1988</year>;<volume>8</volume>(<issue>5</issue>):<fpage>1151</fpage>–<lpage>1157</lpage>.</citation>
         </ref>
         <ref id="bibr5-0885066611408692">
            <label>5</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Martin</surname>
                     <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Schrier</surname>
                     <given-names>RW</given-names>
                  </name>
               </person-group>. <article-title>Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis</article-title>. <source>N Engl J Med</source>. <year>Aug 20 1998</year>;<volume>339</volume>(<issue>8</issue>):<fpage>533</fpage>–<lpage>541</lpage>.</citation>
         </ref>
         <ref id="bibr6-0885066611408692">
            <label>6</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Mitchell</surname>
                     <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kohlhaas</surname>
                     <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sorrentino</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Warner</surname>
                     <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Murad</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Vane</surname>
                     <given-names>JR</given-names>
                  </name>
               </person-group>. <article-title>Induction by endotoxin of nitric oxide synthase in the rat mesentery: lack of effect on action of vasoconstrictors</article-title>. <source>Br J Pharmacol</source>. <year>May 1993</year>;<volume>109</volume>(<issue>1</issue>):<fpage>265</fpage>–<lpage>270</lpage>.</citation>
         </ref>
         <ref id="bibr7-0885066611408692">
            <label>7</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Laffi</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Foschi</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Masini</surname>
                     <given-names>E</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation</article-title>. <source>Hepatology</source>. <year>Dec 1995</year>;<volume>22</volume>(<issue>6</issue>):<fpage>1666</fpage>–<lpage>1673</lpage>.</citation>
         </ref>
         <ref id="bibr8-0885066611408692">
            <label>8</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Fernandez-Seara</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Prieto</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Quiroga</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure</article-title>. <source>Gastroenterology</source>. <year>Nov 1989</year>;<volume>97</volume>(<issue>5</issue>):<fpage>1304</fpage>–<lpage>1312</lpage>.</citation>
         </ref>
         <ref id="bibr9-0885066611408692">
            <label>9</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Maroto</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction</article-title>. <source>Hepatology</source>. <year>1993</year>;<volume>17</volume>(<issue>5</issue>):<fpage>788</fpage>–<lpage>793</lpage>.</citation>
         </ref>
         <ref id="bibr10-0885066611408692">
            <label>10</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bru</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Increased cerebrovascular resistance in cirrhotic patients with ascites</article-title>. <source>Hepatology</source>. <year>1998</year>;<volume>28</volume>(<issue>1</issue>):<fpage>39</fpage>–<lpage>44</lpage>.</citation>
         </ref>
         <ref id="bibr11-0885066611408692">
            <label>11</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Oliver</surname>
                     <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Verna</surname>
                     <given-names>EC</given-names>
                  </name>
               </person-group>. <article-title>Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome</article-title>. <source>Kidney Int</source>. <year>Apr 2010</year>;<volume>77</volume>(<issue>8</issue>):<fpage>669</fpage>–<lpage>680</lpage>.</citation>
         </ref>
         <ref id="bibr12-0885066611408692">
            <label>12</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Rimola</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome)</article-title>. <source>J Hepatol</source>. <year>1986</year>;<volume>3</volume>(<issue>1</issue>):<fpage>111</fpage>–<lpage>117</lpage>.</citation>
         </ref>
         <ref id="bibr13-0885066611408692">
            <label>13</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Laffi</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>La Villa</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pinzani</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Altered renal and platelet arachidonic acid metabolism in cirrhosis</article-title>. <source>Gastroenterology</source>. <year>Feb 1986</year>;<volume>90</volume>(<issue>2</issue>):<fpage>274</fpage>–<lpage>282</lpage>.</citation>
         </ref>
         <ref id="bibr14-0885066611408692">
            <label>14</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Boyer</surname>
                     <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zia</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Reynolds</surname>
                     <given-names>TB</given-names>
                  </name>
               </person-group>. <article-title>Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease</article-title>. <source>Gastroenterology</source>. <year>Aug 1979</year>;<volume>77</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>222</lpage>.</citation>
         </ref>
         <ref id="bibr15-0885066611408692">
            <label>15</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Govindarajan</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Nast</surname>
                     <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Smith</surname>
                     <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Koyle</surname>
                     <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Daskalopoulos</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zipser</surname>
                     <given-names>RD</given-names>
                  </name>
               </person-group>. <article-title>Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome</article-title>. <source>Hepatology</source>. <year>Jul-Aug 1987</year>;<volume>7</volume>(<issue>4</issue>):<fpage>654</fpage>–<lpage>659</lpage>.</citation>
         </ref>
         <ref id="bibr16-0885066611408692">
            <label>16</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Navasa</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Follo</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Filella</surname>
                     <given-names>X</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality</article-title>. <source>Hepatology</source>. <year>May 1998</year>;<volume>27</volume>(<issue>5</issue>):<fpage>1227</fpage>–<lpage>1232</lpage>.</citation>
         </ref>
         <ref id="bibr17-0885066611408692">
            <label>17</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ruiz-del-Arbol</surname>
                     <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Urman</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fernandez</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis</article-title>. <source>Hepatology</source>. <year>2003</year>;<volume>38</volume>(<issue>5</issue>):<fpage>1210</fpage>–<lpage>1218</lpage>.</citation>
         </ref>
         <ref id="bibr18-0885066611408692">
            <label>18</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ruiz-del-Arbol</surname>
                     <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Monescillo</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arocena</surname>
                     <given-names>C</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Circulatory function and hepatorenal syndrome in cirrhosis</article-title>. <source>Hepatology</source>. <year>Aug 2005</year>;<volume>42</volume>(<issue>2</issue>):<fpage>439</fpage>–<lpage>447</lpage>.</citation>
         </ref>
         <ref id="bibr19-0885066611408692">
            <label>19</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Saba</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Janczewski</surname>
                     <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Baker</surname>
                     <given-names>LC</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}</article-title>. <source>Am J Physiol Heart Circ Physiol</source>. <year>Oct 2005</year>;<volume>289</volume>(<issue>4</issue>):<fpage>H1456</fpage>–<lpage>1467</lpage>.</citation>
         </ref>
         <ref id="bibr20-0885066611408692">
            <label>20</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Myers</surname>
                     <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lee</surname>
                     <given-names>SS</given-names>
                  </name>
               </person-group>. <article-title>Cirrhotic cardiomyopathy and liver transplantation</article-title>. <source>Liver Transpl</source>. <year>2000</year>;<volume>6</volume>(<issue>4 Suppl 1</issue>):<fpage>S44</fpage>–<lpage>52</lpage>.</citation>
         </ref>
         <ref id="bibr21-0885066611408692">
            <label>21</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Pozzi</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Carugo</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Boari</surname>
                     <given-names>G</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites</article-title>. <source>Hepatology</source>. <year>Nov 1997</year>;<volume>26</volume>(<issue>5</issue>):<fpage>1131</fpage>–<lpage>1137</lpage>.</citation>
         </ref>
         <ref id="bibr22-0885066611408692">
            <label>22</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Tsai</surname>
                     <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Peng</surname>
                     <given-names>YS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Chen</surname>
                     <given-names>YC</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock</article-title>. <source>Hepatology</source>. <year>Apr 2006</year>;<volume>43</volume>(<issue>4</issue>):<fpage>673</fpage>–<lpage>681</lpage>.</citation>
         </ref>
         <ref id="bibr23-0885066611408692">
            <label>23</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Fernandez</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Escorsell</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zabalza</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival</article-title>. <source>Hepatology</source>. <year>Nov 2006</year>;<volume>44</volume>(<issue>5</issue>):<fpage>1288</fpage>–<lpage>1295</lpage>.</citation>
         </ref>
         <ref id="bibr24-0885066611408692">
            <label>24</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Davis</surname>
                     <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wilkinson</surname>
                     <given-names>AH</given-names>
                  </name>
               </person-group>. <article-title>Identification of patients best suited for combined liver-kidney transplantation: part II</article-title>. <source>Liver Transpl</source>. <year>Mar 2002</year>;<volume>8</volume>(<issue>3</issue>):<fpage>193</fpage>–<lpage>211</lpage>.</citation>
         </ref>
         <ref id="bibr25-0885066611408692">
            <label>25</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gerbes</surname>
                     <given-names>AL</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club</article-title>. <source>Hepatology</source>. <year>Jan 1996</year>;<volume>23</volume>(<issue>1</issue>):<fpage>164</fpage>–<lpage>176</lpage>.</citation>
         </ref>
         <ref id="bibr26-0885066611408692">
            <label>26</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Salerno</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gerbes</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wong</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
               </person-group>. <article-title>Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis</article-title>. <source>Gut</source>. <year>September 1, 2007 2007</year>;<volume>56</volume>(<issue>9</issue>):<fpage>1310</fpage>–<lpage>1318</lpage>.</citation>
         </ref>
         <ref id="bibr27-0885066611408692">
            <label>27</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rodes</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>Hepatorenal syndrome</article-title>. <source>Lancet</source>. <year>Nov 29 2003</year>;<volume>362</volume>(<issue>9398</issue>):<fpage>1819</fpage>–<lpage>1827</lpage>.</citation>
         </ref>
         <ref id="bibr28-0885066611408692">
            <label>28</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Watt</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Uhanova</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Minuk</surname>
                     <given-names>GY</given-names>
                  </name>
               </person-group>. <article-title>Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center</article-title>. <source>Am J Gastroenterol</source>. <year>Aug 2002</year>;<volume>97</volume>(<issue>8</issue>):<fpage>2046</fpage>–<lpage>2050</lpage>.</citation>
         </ref>
         <ref id="bibr29-0885066611408692">
            <label>29</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Colle</surname>
                     <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Durand</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pessione</surname>
                     <given-names>F</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis</article-title>. <source>J Gastroenterol Hepatol</source>. <year>Aug 2002</year>;<volume>17</volume>(<issue>8</issue>):<fpage>882</fpage>–<lpage>888</lpage>.</citation>
         </ref>
         <ref id="bibr30-0885066611408692">
            <label>30</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wong</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pantea</surname>
                     <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sniderman</surname>
                     <given-names>K</given-names>
                  </name>
               </person-group>. <article-title>Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome</article-title>. <source>Hepatology</source>. <year>Jul 2004</year>;<volume>40</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>64</lpage>.</citation>
         </ref>
         <ref id="bibr31-0885066611408692">
            <label>31</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Péron</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bureau</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gonzalez</surname>
                     <given-names>L</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Treatment of Hepatorenal Syndrome as Defined by the International Ascites Club by Albumin and Furosemide Infusion According to the Central Venous Pressure: A Prospective Pilot Study</article-title>. <source>Ame J Gastroenterol</source>. <year>2005</year>;<volume>100</volume>:<fpage>2702</fpage>–<lpage>2707</lpage>.</citation>
         </ref>
         <ref id="bibr32-0885066611408692">
            <label>32</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Follo</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Llovet</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Navasa</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis</article-title>. <source>Hepatology</source>. <year>Dec 1994</year>;<volume>20</volume>(<issue>6</issue>):<fpage>1495</fpage>–<lpage>1501</lpage>.</citation>
         </ref>
         <ref id="bibr33-0885066611408692">
            <label>33</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Sort</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Navasa</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis</article-title>. <source>N Engl J Med</source>. <year>Aug 5 1999</year>;<volume>341</volume>(<issue>6</issue>):<fpage>403</fpage>–<lpage>409</lpage>.</citation>
         </ref>
         <ref id="bibr34-0885066611408692">
            <label>34</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Escorsell</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites</article-title>. <source>Gastroenterology</source>. <year>Jul 1993</year>;<volume>105</volume>(<issue>1</issue>):<fpage>229</fpage>–<lpage>236</lpage>.</citation>
         </ref>
         <ref id="bibr35-0885066611408692">
            <label>35</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Akriviadis</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Botla</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Briggs</surname>
                     <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Han</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Reynolds</surname>
                     <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Shakil</surname>
                     <given-names>O</given-names>
                  </name>
               </person-group>. <article-title>Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial</article-title>. <source>Gastroenterology</source>. <year>Dec 2000</year>;<volume>119</volume>(<issue>6</issue>):<fpage>1637</fpage>–<lpage>1648</lpage>.</citation>
         </ref>
         <ref id="bibr36-0885066611408692">
            <label>36</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Cardenas</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Uriz</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis</article-title>. <source>Hepatology</source>. <year>Oct 2001</year>;<volume>34</volume>(<issue>4 Pt 1</issue>):<fpage>671</fpage>–<lpage>676</lpage>.</citation>
         </ref>
         <ref id="bibr37-0885066611408692">
            <label>37</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wu</surname>
                     <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Yeung</surname>
                     <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Tsai</surname>
                     <given-names>WS</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis</article-title>. <source>Clin Nephrol</source>. <year>Jan 2006</year>;<volume>65</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>33</lpage>.</citation>
         </ref>
         <ref id="bibr38-0885066611408692">
            <label>38</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Hampel</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bynum</surname>
                     <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zamora</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>El-Serag</surname>
                     <given-names>HB</given-names>
                  </name>
               </person-group>. <article-title>Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis</article-title>. <source>Am J Gastroenterol</source>. <year>Jul 2001</year>;<volume>96</volume>(<issue>7</issue>):<fpage>2206</fpage>–<lpage>2210</lpage>.</citation>
         </ref>
         <ref id="bibr39-0885066611408692">
            <label>39</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Montoliu</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Balleste</surname>
                     <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Planas</surname>
                     <given-names>R</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>Jul 2010</year>;<volume>8</volume>(<issue>7</issue>):<fpage>616</fpage>–<lpage>622</lpage>.<comment>; quiz e680</comment>.
</citation>
         </ref>
         <ref id="bibr40-0885066611408692">
            <label>40</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Fraley</surname>
                     <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Burr</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bernardini</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Angus</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kramer</surname>
                     <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Johnson</surname>
                     <given-names>JP</given-names>
                  </name>
               </person-group>. <article-title>Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation</article-title>. <source>Kidney Int</source>. <year>Aug 1998</year>;<volume>54</volume>(<issue>2</issue>):<fpage>518</fpage>–<lpage>524</lpage>.</citation>
         </ref>
         <ref id="bibr41-0885066611408692">
            <label>41</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Moreau</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Durand</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Poynard</surname>
                     <given-names>T</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study</article-title>. <source>Gastroenterology</source>. <year>Apr 2002</year>;<volume>122</volume>(<issue>4</issue>):<fpage>923</fpage>–<lpage>930</lpage>.</citation>
         </ref>
         <ref id="bibr42-0885066611408692">
            <label>42</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wong</surname>
                     <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Blackley</surname>
                     <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Andreoni</surname>
                     <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Chin</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Falk</surname>
                     <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Klemmer</surname>
                     <given-names>PJ</given-names>
                  </name>
               </person-group>. <article-title>Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy</article-title>. <source>Kidney Int</source>. <year>Jul 2005</year>;<volume>68</volume>(<issue>1</issue>):<fpage>362</fpage>–<lpage>370</lpage>.</citation>
         </ref>
         <ref id="bibr43-0885066611408692">
            <label>43</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Alessandria</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ozdogan</surname>
                     <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation</article-title>. <source>Hepatology</source>. <year>Jun 2005</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1282</fpage>–<lpage>1289</lpage>.</citation>
         </ref>
         <ref id="bibr44-0885066611408692">
            <label>44</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Fernandez</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Navasa</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Planas</surname>
                     <given-names>R</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis</article-title>. <source>Gastroenterology</source>. <year>Sep 2007</year>;<volume>133</volume>(<issue>3</issue>):<fpage>818</fpage>–<lpage>824</lpage>.</citation>
         </ref>
         <ref id="bibr45-0885066611408692">
            <label>45</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Rasaratnam</surname>
                     <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kaye</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jennings</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Dudley</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Chin-Dusting</surname>
                     <given-names>J</given-names>
                  </name>
               </person-group>. <article-title>The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial</article-title>. <source>Ann Intern Med</source>. <year>Aug 5 2003</year>;<volume>139</volume>(<issue>3</issue>):<fpage>186</fpage>–<lpage>193</lpage>.</citation>
         </ref>
         <ref id="bibr46-0885066611408692">
            <label>46</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wiest</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Garcia-Tsao</surname>
                     <given-names>G</given-names>
                  </name>
               </person-group>. <article-title>Bacterial translocation (BT) in cirrhosis</article-title>. <source>Hepatology</source>. <year>Mar 2005</year>;<volume>41</volume>(<issue>3</issue>):<fpage>422</fpage>–<lpage>433</lpage>.</citation>
         </ref>
         <ref id="bibr47-0885066611408692">
            <label>47</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Quinlan</surname>
                     <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Martin</surname>
                     <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Evans</surname>
                     <given-names>TW</given-names>
                  </name>
               </person-group>. <article-title>Albumin: biochemical properties and therapeutic potential</article-title>. <source>Hepatology</source>. <year>Jun 2005</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1211</fpage>–<lpage>1219</lpage>.</citation>
         </ref>
         <ref id="bibr48-0885066611408692">
            <label>48</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Quinlan</surname>
                     <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mumby</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Martin</surname>
                     <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bernard</surname>
                     <given-names>GR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gutteridge</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Evans</surname>
                     <given-names>TW</given-names>
                  </name>
               </person-group>. <article-title>Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury</article-title>. <source>Crit Care Med</source>. <year>Mar 2004</year>;<volume>32</volume>(<issue>3</issue>):<fpage>755</fpage>–<lpage>759</lpage>.</citation>
         </ref>
         <ref id="bibr49-0885066611408692">
            <label>49</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fernandez-Esparrach</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Monescillo</surname>
                     <given-names>A</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis</article-title>. <source>Gastroenterology</source>. <year>Oct 1996</year>;<volume>111</volume>(<issue>4</issue>):<fpage>1002</fpage>–<lpage>1010</lpage>.</citation>
         </ref>
         <ref id="bibr50-0885066611408692">
            <label>50</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Garcia-Compean</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Blanc</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Larrey</surname>
                     <given-names>D</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial</article-title>. <source>Ann Hepatol</source>. <year>Jan-Mar 2002</year>;<volume>1</volume>(<issue>1</issue>):<fpage>29</fpage>–<lpage>35</lpage>.</citation>
         </ref>
         <ref id="bibr51-0885066611408692">
            <label>51</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Umgelter</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Reindl</surname>
                     <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wagner</surname>
                     <given-names>KS</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial</article-title>. <source>Crit Care</source>. <year>2008</year>;<volume>12</volume>(<issue>1</issue>):<fpage>R4</fpage>.</citation>
         </ref>
         <ref id="bibr52-0885066611408692">
            <label>52</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Charlton</surname>
                     <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wall</surname>
                     <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ojo</surname>
                     <given-names>AO</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation</article-title>. <source>Liver Transplantation</source>. <year>2009</year>;<volume>15</volume>(<issue>11</issue>):<fpage>S1</fpage>–<lpage>S34</lpage>.</citation>
         </ref>
         <ref id="bibr53-0885066611408692">
            <label>53</label>
            <citation citation-type="journal" xlink:type="simple">. <article-title>EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis</article-title>. <source>J Hepatol</source>. <year>Sep 2010</year>;<volume>53</volume>(<issue>3</issue>):<fpage>397</fpage>–<lpage>417</lpage>.</citation>
         </ref>
         <ref id="bibr54-0885066611408692">
            <label>54</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Richards</surname>
                     <given-names>WO</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Scovill</surname>
                     <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Shin</surname>
                     <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Reed</surname>
                     <given-names>W</given-names>
                  </name>
               </person-group>. <article-title>Acute renal failure associated with increased intra-abdominal pressure</article-title>. <source>Ann Surg</source>. <year>Feb 1983</year>;<volume>197</volume>(<issue>2</issue>):<fpage>183</fpage>–<lpage>187</lpage>.</citation>
         </ref>
         <ref id="bibr55-0885066611408692">
            <label>55</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Umgelter</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Reindl</surname>
                     <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Franzen</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lenhardt</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Huber</surname>
                     <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Schmid</surname>
                     <given-names>RM</given-names>
                  </name>
               </person-group>. <article-title>Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites</article-title>. <source>Intensive Care Med</source>. <year>Jan 2009</year>;<volume>35</volume>(<issue>1</issue>):<fpage>152</fpage>–<lpage>156</lpage>.</citation>
         </ref>
         <ref id="bibr56-0885066611408692">
            <label>56</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Cardenas</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis</article-title>. <source>Semin Nephrol</source>. <year>2001</year>;<volume>21</volume>(<issue>3</issue>):<fpage>308</fpage>–<lpage>316</lpage>.</citation>
         </ref>
         <ref id="bibr57-0885066611408692">
            <label>57</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Barnardo</surname>
                     <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Baldus</surname>
                     <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Maher</surname>
                     <given-names>FT</given-names>
                  </name>
               </person-group>. <article-title>Effects of dopamine on renal function in patients with cirrhosis</article-title>. <source>Gastroenterology</source>. <year>Apr 1970</year>;<volume>58</volume>(<issue>4</issue>):<fpage>524</fpage>–<lpage>531</lpage>.</citation>
         </ref>
         <ref id="bibr58-0885066611408692">
            <label>58</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Bennett</surname>
                     <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Keeffe</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Melnyk</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mahler</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rosch</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Porter</surname>
                     <given-names>GA</given-names>
                  </name>
               </person-group>. <article-title>Response to dopamine hydrochloride in the hepatorenal syndrome</article-title>. <source>Arch Intern Med</source>. <year>Jul 1975</year>;<volume>135</volume>(<issue>7</issue>):<fpage>964</fpage>–<lpage>971</lpage>.</citation>
         </ref>
         <ref id="bibr59-0885066611408692">
            <label>59</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Salmeron</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure</article-title>. <source>J Hepatol</source>. <year>1993</year>;<volume>17</volume>(<issue>2</issue>):<fpage>220</fpage>–<lpage>226</lpage>.</citation>
         </ref>
         <ref id="bibr60-0885066611408692">
            <label>60</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Clewell</surname>
                     <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Walker-Renard</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Prostaglandins for the treatment of hepatorenal syndrome</article-title>. <source>Ann Pharmacother</source>. <year>Jan 1994</year>;<volume>28</volume>(<issue>1</issue>):<fpage>54</fpage>–<lpage>55</lpage>.</citation>
         </ref>
         <ref id="bibr61-0885066611408692">
            <label>61</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fernandez-Esparrach</surname>
                     <given-names>G</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion</article-title>. <source>Hepatology</source>. <year>Jan 1998</year>;<volume>27</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>41</lpage>.</citation>
         </ref>
         <ref id="bibr62-0885066611408692">
            <label>62</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Lenz</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Hortnagl</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Druml</surname>
                     <given-names>W</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis</article-title>. <source>Gut</source>. <year>Jan 1989</year>;<volume>30</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>96</lpage>.</citation>
         </ref>
         <ref id="bibr63-0885066611408692">
            <label>63</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gulberg</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bilzer</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gerbes</surname>
                     <given-names>AL</given-names>
                  </name>
               </person-group>. <article-title>Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine</article-title>. <source>Hepatology</source>. <year>Oct 1999</year>;<volume>30</volume>(<issue>4</issue>):<fpage>870</fpage>–<lpage>875</lpage>.</citation>
         </ref>
         <ref id="bibr64-0885066611408692">
            <label>64</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ryckwaert</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Virsolvy</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fort</surname>
                     <given-names>A</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance</article-title>. <source>Crit Care Med</source>. <year>Mar 2009</year>;<volume>37</volume>(<issue>3</issue>):<fpage>876</fpage>–<lpage>881</lpage>.</citation>
         </ref>
         <ref id="bibr65-0885066611408692">
            <label>65</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ortega</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Uriz</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study</article-title>. <source>Hepatology</source>. <year>Oct 2002</year>;<volume>36</volume>(<issue>4 Pt 1</issue>):<fpage>941</fpage>–<lpage>948</lpage>.</citation>
         </ref>
         <ref id="bibr66-0885066611408692">
            <label>66</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Uriz</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Cardenas</surname>
                     <given-names>A</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome</article-title>. <source>J Hepatol</source>. <year>Jul 2000</year>;<volume>33</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>48</lpage>.</citation>
         </ref>
         <ref id="bibr67-0885066611408692">
            <label>67</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Alessandria</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Venon</surname>
                     <given-names>WD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Marzano</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Barletti</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fadda</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rizzetto</surname>
                     <given-names>M</given-names>
                  </name>
               </person-group>. <article-title>Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>Dec 2002</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1363</fpage>–<lpage>1368</lpage>.</citation>
         </ref>
         <ref id="bibr68-0885066611408692">
            <label>68</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Solanki</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Chawla</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Garg</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gupta</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jain</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sarin</surname>
                     <given-names>SK</given-names>
                  </name>
               </person-group>. <article-title>Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial</article-title>. <source>J Gastroenterol Hepatol</source>. <year>Feb 2003</year>;<volume>18</volume>(<issue>2</issue>):<fpage>152</fpage>–<lpage>156</lpage>.</citation>
         </ref>
         <ref id="bibr69-0885066611408692">
            <label>69</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Narahara</surname>
                     <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kanazawa</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Taki</surname>
                     <given-names>Y</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis</article-title>. <source>J Gastroenterol Hepatol</source>. <year>Nov 2009</year>;<volume>24</volume>(<issue>11</issue>):<fpage>1791</fpage>–<lpage>1797</lpage>.</citation>
         </ref>
         <ref id="bibr70-0885066611408692">
            <label>70</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Martin-Llahi</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Pepin</surname>
                     <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study</article-title>. <source>Gastroenterology</source>. <year>May 2008</year>;<volume>134</volume>(<issue>5</issue>):<fpage>1352</fpage>–<lpage>1359</lpage>.</citation>
         </ref>
         <ref id="bibr71-0885066611408692">
            <label>71</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Sanyal</surname>
                     <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Boyer</surname>
                     <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Garcia-Tsao</surname>
                     <given-names>G</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome</article-title>. <source>Gastroenterology</source>. <year>2008</year>;<volume>134</volume>(<issue>5</issue>):<fpage>1360</fpage>–<lpage>1368</lpage>.</citation>
         </ref>
         <ref id="bibr72-0885066611408692">
            <label>72</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Peron</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bureau</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gonzalez</surname>
                     <given-names>L</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study</article-title>. <source>Am J Gastroenterol</source>. <year>Dec 2005</year>;<volume>100</volume>(<issue>12</issue>):<fpage>2702</fpage>–<lpage>2707</lpage>.</citation>
         </ref>
         <ref id="bibr73-0885066611408692">
            <label>73</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Fernandez</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Monteagudo</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bargallo</surname>
                     <given-names>X</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis</article-title>. <source>Hepatology</source>. <year>Sep 2005</year>;<volume>42</volume>(<issue>3</issue>):<fpage>627</fpage>–<lpage>634</lpage>.</citation>
         </ref>
         <ref id="bibr74-0885066611408692">
            <label>74</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Pomier-Layrargues</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Paquin</surname>
                     <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Hassoun</surname>
                     <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lafortune</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Tran</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study</article-title>. <source>Hepatology</source>. <year>Jul 2003</year>;<volume>38</volume>(<issue>1</issue>):<fpage>238</fpage>–<lpage>243</lpage>.</citation>
         </ref>
         <ref id="bibr75-0885066611408692">
            <label>75</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Angeli</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Volpin</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Piovan</surname>
                     <given-names>D</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites</article-title>. <source>Hepatology</source>. <year>Oct 1998</year>;<volume>28</volume>(<issue>4</issue>):<fpage>937</fpage>–<lpage>943</lpage>.</citation>
         </ref>
         <ref id="bibr76-0885066611408692">
            <label>76</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Angeli</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Volpin</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gerunda</surname>
                     <given-names>G</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide</article-title>. <source>Hepatology</source>. <year>Jun 1999</year>;<volume>29</volume>(<issue>6</issue>):<fpage>1690</fpage>–<lpage>1697</lpage>.</citation>
         </ref>
         <ref id="bibr77-0885066611408692">
            <label>77</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Kiser</surname>
                     <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fish</surname>
                     <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Obritsch</surname>
                     <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jung</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>MacLaren</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Parikh</surname>
                     <given-names>CR</given-names>
                  </name>
               </person-group>. <article-title>Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study</article-title>. <source>Nephrol Dial Transplant</source>. <year>2005</year>;<volume>20</volume>(<issue>9</issue>):<fpage>1813</fpage>–<lpage>1820</lpage>.</citation>
         </ref>
         <ref id="bibr78-0885066611408692">
            <label>78</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Duvoux</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zanditenas</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Hezode</surname>
                     <given-names>C</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study</article-title>. <source>Hepatology</source>. <year>Aug 2002</year>;<volume>36</volume>(<issue>2</issue>):<fpage>374</fpage>–<lpage>380</lpage>.</citation>
         </ref>
         <ref id="bibr79-0885066611408692">
            <label>79</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Dobre</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Demirjian</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sehgal</surname>
                     <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Navaneethan</surname>
                     <given-names>SD</given-names>
                  </name>
               </person-group>. <article-title>Terlipressin in hepatorenal syndrome: a systematic review and meta-analysis</article-title>. <source>Int Urol Nephrol</source>. <year>Mar 20 2010</year>.
</citation>
         </ref>
         <ref id="bibr80-0885066611408692">
            <label>80</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Quiroga</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sangro</surname>
                     <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Nunez</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters</article-title>. <source>Hepatology</source>. <year>Apr 1995</year>;<volume>21</volume>(<issue>4</issue>):<fpage>986</fpage>–<lpage>994</lpage>.</citation>
         </ref>
         <ref id="bibr81-0885066611408692">
            <label>81</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Somberg</surname>
                     <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lake</surname>
                     <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Tomlanovich</surname>
                     <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>LaBerge</surname>
                     <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Feldstein</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bass</surname>
                     <given-names>NM</given-names>
                  </name>
               </person-group>. <article-title>Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function</article-title>. <source>Hepatology</source>. <year>Mar 1995</year>;<volume>21</volume>(<issue>3</issue>):<fpage>709</fpage>–<lpage>716</lpage>.</citation>
         </ref>
         <ref id="bibr82-0885066611408692">
            <label>82</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wong</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sniderman</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Liu</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Allidina</surname>
                     <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sherman</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Blendis</surname>
                     <given-names>L</given-names>
                  </name>
               </person-group>. <article-title>Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites</article-title>. <source>Ann Intern Med</source>. <year>Jun 1 1995</year>;<volume>122</volume>(<issue>11</issue>):<fpage>816</fpage>–<lpage>822</lpage>.</citation>
         </ref>
         <ref id="bibr83-0885066611408692">
            <label> 83</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ochs</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rossle</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Haag</surname>
                     <given-names>K</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites</article-title>. <source>N Engl J Med</source>. <year>May 4 1995</year>;<volume>332</volume>(<issue>18</issue>):<fpage>1192</fpage>–<lpage>1197</lpage>.</citation>
         </ref>
         <ref id="bibr84-0885066611408692">
            <label> 84</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wong</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Blendis</surname>
                     <given-names>L</given-names>
                  </name>
               </person-group>. <article-title>Transjugular intrahepatic portosystemic shunt for refractory ascites: tipping the sodium balance</article-title>. <source>Hepatology</source>. <year>Jul 1995</year>;<volume>22</volume>(<issue>1</issue>):<fpage>358</fpage>–<lpage>364</lpage>.</citation>
         </ref>
         <ref id="bibr85-0885066611408692">
            <label> 85</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bandi</surname>
                     <given-names>JC</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems</article-title>. <source>Hepatology</source>. <year>Aug 1998</year>;<volume>28</volume>(<issue>2</issue>):<fpage>416</fpage>–<lpage>422</lpage>.</citation>
         </ref>
         <ref id="bibr86-0885066611408692">
            <label> 86</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Brensing</surname>
                     <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Textor</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Perz</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study</article-title>. <source>Gut</source>. <year>Aug 2000</year>;<volume>47</volume>(<issue>2</issue>):<fpage>288</fpage>–<lpage>295</lpage>.</citation>
         </ref>
         <ref id="bibr87-0885066611408692">
            <label> 87</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gluud</surname>
                     <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Christensen</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Christensen</surname>
                     <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Krag</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome</article-title>. <source>Hepatology</source>. <year>2010</year>;<volume>51</volume>(<issue>2</issue>):<fpage>576</fpage>–<lpage>584</lpage>.</citation>
         </ref>
         <ref id="bibr88-0885066611408692">
            <label> 88</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Restuccia</surname>
                     <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ortega</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Guevara</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study</article-title>. <source>J Hepatol</source>. <year>Jan 2004</year>;<volume>40</volume>(<issue>1</issue>):<fpage>140</fpage>–<lpage>146</lpage>.</citation>
         </ref>
         <ref id="bibr89-0885066611408692">
            <label> 89</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wilkinson</surname>
                     <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Weston</surname>
                     <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Parsons</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Williams</surname>
                     <given-names>R</given-names>
                  </name>
               </person-group>. <article-title>Dialysis in the treatment of renal failure in patients with liver disease</article-title>. <source>Clin Nephrol</source>. <year>Jul 1977</year>;<volume>8</volume>(<issue>1</issue>):<fpage>287</fpage>–<lpage>292</lpage>.</citation>
         </ref>
         <ref id="bibr90-0885066611408692">
            <label> 90</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ellis</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Avner</surname>
                     <given-names>ED</given-names>
                  </name>
               </person-group>. <article-title>Renal failure and dialysis therapy in children with hepatic failure in the perioperative period of orthotopic liver transplantation</article-title>. <source>Clin Nephrol</source>. <year>Jun 1986</year>;<volume>25</volume>(<issue>6</issue>):<fpage>295</fpage>–<lpage>303</lpage>.</citation>
         </ref>
         <ref id="bibr91-0885066611408692">
            <label> 91</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Keller</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Heinze</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jochimsen</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Passfall</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Schuppan</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Buttner</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis</article-title>. <source>Ren Fail</source>. <year>Mar 1995</year>;<volume>17</volume>(<issue>2</issue>):<fpage>135</fpage>–<lpage>146</lpage>.</citation>
         </ref>
         <ref id="bibr92-0885066611408692">
            <label> 92</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Capling</surname>
                     <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bastani</surname>
                     <given-names>B</given-names>
                  </name>
               </person-group>. <article-title>The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis</article-title>. <source>Ren Fail</source>. <year>Sep 2004</year>;<volume>26</volume>(<issue>5</issue>):<fpage>563</fpage>–<lpage>568</lpage>.</citation>
         </ref>
         <ref id="bibr93-0885066611408692">
            <label> 93</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Davenport</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Renal replacement therapy in the patient with acute brain injury</article-title>. <source>Am J Kidney Dis</source>. <year>Mar 2001</year>;<volume>37</volume>(<issue>3</issue>):<fpage>457</fpage>–<lpage>466</lpage>.</citation>
         </ref>
         <ref id="bibr94-0885066611408692">
            <label> 94</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Davenport</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Will</surname>
                     <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Davison</surname>
                     <given-names>AM</given-names>
                  </name>
               </person-group>. <article-title>Effect of renal replacement therapy on patients with combined acute renal and fulminant hepatic failure</article-title>. <source>Kidney Int Suppl</source>. <year>Jun 1993</year>;<volume>41</volume>:<fpage>S245</fpage>–<lpage>251</lpage>.</citation>
         </ref>
         <ref id="bibr95-0885066611408692">
            <label> 95</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Davenport</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Will</surname>
                     <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Davidson</surname>
                     <given-names>AM</given-names>
                  </name>
               </person-group>. <article-title>Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure</article-title>. <source>Crit Care Med</source>. <year>Mar 1993</year>;<volume>21</volume>(<issue>3</issue>):<fpage>328</fpage>–<lpage>338</lpage>.</citation>
         </ref>
         <ref id="bibr96-0885066611408692">
            <label> 96</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Detry</surname>
                     <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Arkadopoulos</surname>
                     <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ting</surname>
                     <given-names>P</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Intracranial pressure during liver transplantation for fulminant hepatic failure</article-title>. <source>Transplantation</source>. <year>Mar 15 1999</year>;<volume>67</volume>(<issue>5</issue>):<fpage>767</fpage>–<lpage>770</lpage>.</citation>
         </ref>
         <ref id="bibr97-0885066611408692">
            <label> 97</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>De Vriese</surname>
                     <given-names>AS</given-names>
                  </name>
               </person-group>. <article-title>Prevention and treatment of acute renal failure in sepsis</article-title>. <source>J Am Soc Nephrol</source>. <year>Mar 2003</year>;<volume>14</volume>(<issue>3</issue>):<fpage>792</fpage>–<lpage>805</lpage>.</citation>
         </ref>
         <ref id="bibr98-0885066611408692">
            <label> 98</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>De Vriese</surname>
                     <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Colardyn</surname>
                     <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Philippe</surname>
                     <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Vanholder</surname>
                     <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>De Sutter</surname>
                     <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Lameire</surname>
                     <given-names>NH</given-names>
                  </name>
               </person-group>. <article-title>Cytokine removal during continuous hemofiltration in septic patients</article-title>. <source>J Am Soc Nephrol</source>. <year>Apr 1999</year>;<volume>10</volume>(<issue>4</issue>):<fpage>846</fpage>–<lpage>853</lpage>.</citation>
         </ref>
         <ref id="bibr99-0885066611408692">
            <label> 99</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>McClain</surname>
                     <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Barve</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Deaciuc</surname>
                     <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kugelmas</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Hill</surname>
                     <given-names>D</given-names>
                  </name>
               </person-group>. <article-title>Cytokines in alcoholic liver disease</article-title>. <source>Semin Liver Dis</source>. <year>1999</year>;<volume>19</volume>(<issue>2</issue>):<fpage>205</fpage>–<lpage>219</lpage>.</citation>
         </ref>
         <ref id="bibr100-0885066611408692">
            <label>100</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Witzke</surname>
                     <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Baumann</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Patschan</surname>
                     <given-names>D</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Which patients benefit from hemodialysis therapy in hepatorenal syndrome?</article-title> 
               <source>J Gastroenterol Hepatol</source>. <year>Dec 2004</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1369</fpage>–<lpage>1373</lpage>.</citation>
         </ref>
         <ref id="bibr101-0885066611408692">
            <label>101</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mai</surname>
                     <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Melton</surname>
                     <given-names>LB</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis</article-title>. <source>Transplantation</source>. <year>May 27 2001</year>;<volume>71</volume>(<issue>10</issue>):<fpage>1424</fpage>–<lpage>1428</lpage>.</citation>
         </ref>
         <ref id="bibr102-0885066611408692">
            <label>102</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Bellomo</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Teede</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Boyce</surname>
                     <given-names>N</given-names>
                  </name>
               </person-group>. <article-title>Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study</article-title>. <source>Intensive Care Med</source>. <year>1993</year>;<volume>19</volume>(<issue>6</issue>):<fpage>329</fpage>–<lpage>332</lpage>.</citation>
         </ref>
         <ref id="bibr103-0885066611408692">
            <label>103</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Biancofiore</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Esposito</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bindi</surname>
                     <given-names>L</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients</article-title>. <source>Minerva anestesiologica</source>. <year>Jun 2003</year>;<volume>69</volume>(<issue>6</issue>):<fpage>527</fpage>–<lpage>534</lpage>; <fpage>534</fpage>–<lpage>528</lpage>.
</citation>
         </ref>
         <ref id="bibr104-0885066611408692">
            <label>104</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Liu</surname>
                     <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Himmelfarb</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Paganini</surname>
                     <given-names>E</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Timing of Initiation of Dialysis in Critically Ill Patients with Acute Kidney Injury</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>September 1, 2006 2006</year>;<volume>1</volume>(<issue>5</issue>):<fpage>915</fpage>–<lpage>919</lpage>.</citation>
         </ref>
         <ref id="bibr105-0885066611408692">
            <label>105</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Payen</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>de Pont</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sakr</surname>
                     <given-names>Y</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>A positive fluid balance is associated with a worse outcome in patients with acute renal failure</article-title>. <source>Critical Care</source>. <year>2008</year>;<volume>12</volume>(<issue>3</issue>):<fpage>R74</fpage>.</citation>
         </ref>
         <ref id="bibr106-0885066611408692">
            <label>106</label>
            <citation citation-type="journal" xlink:type="simple">. <article-title>Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury</article-title>. <source>New England Journal of Medicine</source>. <year>2008</year>;<volume>359</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>20</lpage>.</citation>
         </ref>
         <ref id="bibr107-0885066611408692">
            <label>107</label>
            <citation citation-type="journal" xlink:type="simple">. <article-title>Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients</article-title>. <source>New England Journal of Medicine</source>. <year>2009</year>;<volume>361</volume>(<issue>17</issue>):<fpage>1627</fpage>–<lpage>1638</lpage>.</citation>
         </ref>
         <ref id="bibr108-0885066611408692">
            <label>108</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Piccinni</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Dan</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Barbacini</surname>
                     <given-names>S</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Early isovolaemic haemofiltration in oliguric patients with septic shock</article-title>. <source>Intensive Care Med</source>. <year>Jan 2006</year>;<volume>32</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>86</lpage>.</citation>
         </ref>
         <ref id="bibr109-0885066611408692">
            <label>109</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Mitzner</surname>
                     <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Stange</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Klammt</surname>
                     <given-names>S</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial</article-title>. <source>Liver Transpl</source>. <year>May 2000</year>;<volume>6</volume>(<issue>3</issue>):<fpage>277</fpage>–<lpage>286</lpage>.</citation>
         </ref>
         <ref id="bibr110-0885066611408692">
            <label>110</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Faubion</surname>
                     <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Guicciardi</surname>
                     <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Miyoshi</surname>
                     <given-names>H</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas</article-title>. <source>J Clin Invest</source>. <year>Jan 1999</year>;<volume>103</volume>(<issue>1</issue>):<fpage>137</fpage>–<lpage>145</lpage>.</citation>
         </ref>
         <ref id="bibr111-0885066611408692">
            <label>111</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Bomzon</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Holt</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Moore</surname>
                     <given-names>K</given-names>
                  </name>
               </person-group>. <article-title>Bile acids, oxidative stress, and renal function in biliary obstruction</article-title>. <source>Semin Nephrol</source>. <year>Nov 1997</year>;<volume>17</volume>(<issue>6</issue>):<fpage>549</fpage>–<lpage>562</lpage>.</citation>
         </ref>
         <ref id="bibr112-0885066611408692">
            <label>112</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Mitzner</surname>
                     <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Klammt</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Peszynski</surname>
                     <given-names>P</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system</article-title>. <source>Ther Apher</source>. <year>Oct 2001</year>;<volume>5</volume>(<issue>5</issue>):<fpage>417</fpage>–<lpage>422</lpage>.</citation>
         </ref>
         <ref id="bibr113-0885066611408692">
            <label>113</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Oppert</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Rademacher</surname>
                     <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Petrasch</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jorres</surname>
                     <given-names>A</given-names>
                  </name>
               </person-group>. <article-title>Extracorporeal liver support therapy with Prometheus in patients with liver failure in the intensive care unit</article-title>. <source>Ther Apher Dial</source>. <year>Oct 2009</year>;<volume>13</volume>(<issue>5</issue>):<fpage>426</fpage>–<lpage>430</lpage>.</citation>
         </ref>
         <ref id="bibr114-0885066611408692">
            <label>114</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Derek</surname>
                     <given-names>R</given-names>
                  </name>
               </person-group>. <article-title>Townsend SMBMJJDBDCRTNG. Intraoperative renal support during liver transplantation</article-title>. <source>Liver Transplantation</source>. <year>2009</year>;<volume>15</volume>(<issue>1</issue>):<fpage>73</fpage>–<lpage>78</lpage>.</citation>
         </ref>
         <ref id="bibr115-0885066611408692">
            <label>115</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Navasa</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Feu</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Garcia-Pagan</surname>
                     <given-names>JC</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis</article-title>. <source>Hepatology</source>. <year>Mar 1993</year>;<volume>17</volume>(<issue>3</issue>):<fpage>355</fpage>–<lpage>360</lpage>.</citation>
         </ref>
         <ref id="bibr116-0885066611408692">
            <label>116</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Piscaglia</surname>
                     <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Zironi</surname>
                     <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gaiani</surname>
                     <given-names>S</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study</article-title>. <source>Hepatology</source>. <year>Jul 1999</year>;<volume>30</volume>(<issue>1</issue>):<fpage>58</fpage>–<lpage>64</lpage>.</citation>
         </ref>
         <ref id="bibr117-0885066611408692">
            <label>117</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Marik</surname>
                     <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wood</surname>
                     <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Starzl</surname>
                     <given-names>TE</given-names>
                  </name>
               </person-group>. <article-title>The course of type 1 hepato-renal syndrome post liver transplantation</article-title>. <source>Nephrol Dial Transplant</source>. <year>2005</year>;<volume>25</volume>:<fpage>25</fpage>.</citation>
         </ref>
         <ref id="bibr118-0885066611408692">
            <label>118</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ruiz</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Barri</surname>
                     <given-names>YM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jennings</surname>
                     <given-names>LW</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT)</article-title>. <source>Liver Transpl</source>. <year>Jun 2007</year>;<volume>13</volume>(<issue>6</issue>):<fpage>838</fpage>–<lpage>843</lpage>.</citation>
         </ref>
         <ref id="bibr119-0885066611408692">
            <label>119</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Klintmalm</surname>
                     <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Levy</surname>
                     <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Jennings</surname>
                     <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Goldstein</surname>
                     <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Husberg</surname>
                     <given-names>BS</given-names>
                  </name>
               </person-group>. <article-title>Impact of pretransplant renal function on survival after liver transplantation</article-title>. <source>Transplantation</source>. <year>Feb 15 1995</year>;<volume>59</volume>(<issue>3</issue>):<fpage>361</fpage>–<lpage>365</lpage>.</citation>
         </ref>
         <ref id="bibr120-0885066611408692">
            <label>120</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Morris</surname>
                     <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Goldstein</surname>
                     <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Husberg</surname>
                     <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Klintmalm</surname>
                     <given-names>GB</given-names>
                  </name>
               </person-group>. <article-title>Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients</article-title>. <source>Transplantation</source>. <year>Feb 1991</year>;<volume>51</volume>(<issue>2</issue>):<fpage>428</fpage>–<lpage>430</lpage>.</citation>
         </ref>
         <ref id="bibr121-0885066611408692">
            <label>121</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Ruiz</surname>
                     <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Kunitake</surname>
                     <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Wilkinson</surname>
                     <given-names>AH</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Long-term analysis of combined liver and kidney transplantation at a single center</article-title>. <source>Arch Surg</source>. <year>Aug 2006</year>;<volume>141</volume>(<issue>8</issue>):<fpage>735</fpage>–<lpage>741</lpage>.<comment>; discussion 741-732</comment>.
</citation>
         </ref>
         <ref id="bibr122-0885066611408692">
            <label>122</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Eason</surname>
                     <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Davis</surname>
                     <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Sung</surname>
                     <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gerber</surname>
                     <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bloom</surname>
                     <given-names>RD</given-names>
                  </name>
               </person-group>. <article-title>Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK)</article-title>. <source>Am J Transplant</source>. <year>Nov 2008</year>;<volume>8</volume>(<issue>11</issue>):<fpage>2243</fpage>–<lpage>2251</lpage>.</citation>
         </ref>
         <ref id="bibr123-0885066611408692">
            <label>123</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Locke</surname>
                     <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Warren</surname>
                     <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Singer</surname>
                     <given-names>AL</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts</article-title>. <source>Transplantation</source>. <year>Apr 15 2008</year>;<volume>85</volume>(<issue>7</issue>):<fpage>935</fpage>–<lpage>942</lpage>.</citation>
         </ref>
         <ref id="bibr124-0885066611408692">
            <label>124</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
               </person-group>. <article-title>Combined kidney liver transplant in the MELD era: where are we going?</article-title> 
               <source>Liver Transpl</source>. <year>Sep 2005</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1022</fpage>–<lpage>1025</lpage>.</citation>
         </ref>
         <ref id="bibr125-0885066611408692">
            <label>125</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Jeyarajah</surname>
                     <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                     <surname>McBride</surname>
                     <given-names>M</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant</article-title>. <source>Transplantation</source>. <year>Dec 27 1997</year>;<volume>64</volume>(<issue>12</issue>):<fpage>1760</fpage>–<lpage>1765</lpage>.</citation>
         </ref>
         <ref id="bibr126-0885066611408692">
            <label>126</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Simpson</surname>
                     <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Cho</surname>
                     <given-names>YW</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Cicciarelli</surname>
                     <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Selby</surname>
                     <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fong</surname>
                     <given-names>TL</given-names>
                  </name>
               </person-group>. <article-title>Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database</article-title>. <source>Transplantation</source>. <year>Nov 27 2006</year>;<volume>82</volume>(<issue>10</issue>):<fpage>1298</fpage>–<lpage>1303</lpage>.</citation>
         </ref>
         <ref id="bibr127-0885066611408692">
            <label>127</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wadei</surname>
                     <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Geiger</surname>
                     <given-names>XJ</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Cortese</surname>
                     <given-names>C</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy</article-title>. <source>Am J Transplant</source>. <year>Dec 2008</year>;<volume>8</volume>(<issue>12</issue>):<fpage>2618</fpage>–<lpage>2626</lpage>.</citation>
         </ref>
         <ref id="bibr128-0885066611408692">
            <label>128</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Tanriover</surname>
                     <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mejia</surname>
                     <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Weinstein</surname>
                     <given-names>J</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Analysis of kidney function and biopsy results in liver failure patients with renal dysfunction: a new look to combined liver kidney allocation in the post-MELD era</article-title>. <source>Transplantation</source>. <year>Dec 15 2008</year>;<volume>86</volume>(<issue>11</issue>):<fpage>1548</fpage>–<lpage>1553</lpage>.</citation>
         </ref>
         <ref id="bibr129-0885066611408692">
            <label>129</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Halimi</surname>
                     <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bonnard</surname>
                     <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Bernard</surname>
                     <given-names>B</given-names>
                  </name>
                  <etal/>
               </person-group>. <article-title>Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study</article-title>. <source>Eur J Gastroenterol Hepatol</source>. <year>Feb 2002</year>;<volume>14</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>158</lpage>.</citation>
         </ref>
         <ref id="bibr130-0885066611408692">
            <label>130</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Wadei</surname>
                     <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Mai</surname>
                     <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Ahsan</surname>
                     <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gonwa</surname>
                     <given-names>TA</given-names>
                  </name>
               </person-group>. <article-title>Hepatorenal syndrome: pathophysiology and management</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>Sep 2006</year>;<volume>1</volume>(<issue>5</issue>):<fpage>1066</fpage>–<lpage>1079</lpage>.</citation>
         </ref>
         <ref id="bibr131-0885066611408692">
            <label>131</label>
            <citation citation-type="journal" xlink:type="simple">
               <person-group person-group-type="author">
                  <name name-style="western">
                     <surname>Arroyo</surname>
                     <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Fernandez</surname>
                     <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                     <surname>Gines</surname>
                     <given-names>P</given-names>
                  </name>
               </person-group>. <article-title>Pathogenesis and treatment of hepatorenal syndrome</article-title>. <source>Semin Liver Dis</source>. <year>Feb 2008</year>;<volume>28</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>95</lpage>.</citation>
         </ref>
      </ref-list>
   </back>
</article>